DMID #[ADDRESS_1262769] 2019  
 
  
 
DMID/NIAID/NIH           1 
CONFIDENTIAL  
 A Phase I, Randomized, Placebo Controlled, Double -blind, Dose 
Escalation trial to Evaluate the Safety and Immunogenicity of an 
Andes Virus DNA Vaccine for the Prevention of Hantavirus 
Pulmonary Syndrome Using the PharmaJet Stratis® Needle -Free 
Injection System in Normal Healthy Adults  
DMID Protocol Number:   16-0119  
DMID Funding Mecha nism: HHSN272201300016I  
Pharmaceutical Support Provided by: [CONTACT_900596],  [LOCATION_002] Army 
Medical Research Institute of Infectious Diseases  ([LOCATION_003]MRI ID), Aldevron  
IND Sponsor: Division of Microbiology and Infectious Diseases (DMID), Na tional Institute of 
Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)  
Principal Investigator:   [INVESTIGATOR_900570], MD  
DMID Protocol Champi[INVESTIGATOR_2394]:   Gabriele Feolo, RN, MSN  
DMID Medical Officer:   Kay M. Tomashek, MD , MPH  
DMID Medical Monitor:   Jorge Mejia -Galvis , MD  
Version Number: 4.[ADDRESS_1262770]  2019 
 
DMID #[ADDRESS_1262771] 2019  
 
  
 
DMID/NIAID/NIH           2 
CONFIDENTIAL  
 STATEMENT OF COMPLIANCE  
This trial will be carried out in accordance with Good Clinical Practice (GCP) as required by [CONTACT_14504]:  
• [LOCATION_002] (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 
CFR Part 46; 21 CFR Part 50, 21 CFR Part 54, 21 CFR Part 56, and 21 CFR Part 312);  
• International Conference on Harmonisation: Good Clinical Practice (ICH E6); 62 Federal 
Register [ZIP_CODE] (1997); an d future revisions ; 
• The Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule -Final 
Modification (45 CFR Parts 160 and 164);  
• National Institutes of Health (NIH) Clinical Terms of Award, as applicable.  
Compliance with these standards prov ides public assurance that the rights, safety and well -being 
of study subjects are protected, consistent with the principles that have their origin in the 
Declaration of Helsinki.  
All key personnel (all individuals responsible for the design and conduct of  this trial) have 
completed Human Subjects Protection Training.  
 
DMID #[ADDRESS_1262772] 2019  
 
  
 
DMID/NIAID/NIH           3 
CONFIDENTIAL  
 SIGNATURE [CONTACT_19841], and provides 
the necessary assurances that this trial will be conducted according to all stip ulations of the 
protocol, including all statements regarding confidentiality, and according to local legal and 
regulatory requirements and applicable US federal regulations and ICH guidelines.  
 
Site Investigator:  
 
Signed:   Date:   
 Name  
[CONTACT_527881] #[ADDRESS_1262773] 2019  
 
  
 
DMID/NIAID/NIH           [ADDRESS_1262774] of Abbreviations  ................................ ................................ ................................ ..................... 10 
Protocol Summary  ................................ ................................ ................................ ......................... 12 
1 Key Roles  ................................ ................................ ................................ .............................. 18 
2 Background Information and Scientific Rationale  ................................ ............................... 20 
2.1 Background Information  ................................ ................................ ........................... 20 
2.1.1  Safety/Toxicology of similar vaccines ................................ .......................... [ADDRESS_1262775]  ................................ ................................ .39 
DMID #[ADDRESS_1262776] 2019  
 
  
 
DMID/NIAID/NIH           5 
CONFIDENTIAL  
 5.4.4  Study Withdrawal  ................................ ................................ ......................... 41 
5.4.5  Handling of Withdrawals  ................................ ................................ .............. 42 
5.4.6  Termination of Study  ................................ ................................ .................... 43 
6 Study Intervention/Investigational Product  ................................ ................................ .......... [ADDRESS_1262777] Storage and Stability ................................ ................................ ........ 45 
6.2 Dosage, Preparation and Administration of Study Intervention/Investigational 
Product  ................................ ................................ ................................ ...................... 46 
6.3 Modification of Study Intervention/Investigational Product for a Participant  ......... 47 
6.4 Accountability Procedures for the Study Interve ntion/Investigational Product(s)  ...[ADDRESS_1262778] Compliance with Study Intervention/Investigational 
Product  ................................ ................................ ................................ ...................... 49 
6.6 Concomitant Medications/Treatments  ................................ ................................ ......49 
7 Study Schedule ................................ ................................ ................................ ...................... 50 
7.1 Screening ................................ ................................ ................................ ................... 50 
7.2 Enrollment/Baseline  ................................ ................................ ................................ ..[ADDRESS_1262779] each vaccination  ................................ ................................ .55 
7.6 Follow -up Visits ................................ ................................ ................................ ........ 56 
7.7 Final Study Visit  ................................ ................................ ................................ .......56 
7.8 Early Termination Visit  ................................ ................................ ............................ 57 
7.9 Unscheduled Visit  ................................ ................................ ................................ .....57 
8 Study Procedures/Evaluations  ................................ ................................ .............................. 59 
8.1 Clinical Evaluations  ................................ ................................ ................................ ..59 
8.2 Laboratory Evaluations  ................................ ................................ ............................. 60 
8.2.1  Clinical Laboratory Evaluations  ................................ ................................ ...60 
8.2.2  Accepta ble Laboratory Values for Eligibility and Defining Normal 
Values  ................................ ................................ ................................ ........... 62 
8.2.3  Special Assays or Procedures  ................................ ................................ .......63 
8.2.4  Specimen Preparation, Handling, and Shippi[INVESTIGATOR_007]  ................................ ........... 63 
9 Assessment of Safety  ................................ ................................ ................................ ............ 65 
9.1 Specification of Safety Parameters  ................................ ................................ ........... 65 
9.2 Methods and Timing for Assessing, Recording, and Analyzing Safety 
Parameters  ................................ ................................ ................................ ................. 65 
DMID #[ADDRESS_1262780] 2019  
 
  
 
DMID/NIAID/NIH           [ADDRESS_1262781] Halting Rules  ................................ ................................ .....75 
9.5.2  Study Halting Rules  ................................ ................................ ...................... 76 
9.6 Safety Oversight (ISM plus SMC)  ................................ ................................ ............ 77 
9.6.1  Independent Safety Monitor (ISM)  ................................ ............................... 77 
9.6.2  Safety Monitoring Committee (SMC)  ................................ .......................... 78 
10 Clinical Monitoring  ................................ ................................ ................................ ............... 80 
10.1  Site Mon itoring Plan  ................................ ................................ ................................ .80 
11 Statistical Considerations  ................................ ................................ ................................ ......81 
11.1  Study Hypotheses ................................ ................................ ................................ ......81 
11.2  Sample Size Considerations  ................................ ................................ ...................... 81 
11.3  Planned Interim Analyses (if applicable)  ................................ ................................ ..81 
11.3.1  Interim Safety Review  ................................ ................................ .................. 81 
11.3.2  Interim Analysis of Safety and Immunogenicity Data  ................................ .82 
11.4  Final Analysis Plan  ................................ ................................ ................................ ...82 
11.4.1  Analysis Populations  ................................ ................................ ..................... 82 
11.4.2  Safety Data  ................................ ................................ ................................ ....83 
11.4.3  Immunogenicity Data ................................ ................................ .................... 84 
11.4.4  Missing Values and Outliers  ................................ ................................ ......... 84 
12 Source Documents and Access to Source Data/Documents  ................................ ................. 85 
13 Quality Control and Quality Assurance  ................................ ................................ ................ 86 
14 Ethics/Protection of Human Subjects  ................................ ................................ ................... [ADDRESS_1262782]  ................................ ................................ ....................... 87 
14.3  Informed Consent Process  ................................ ................................ ........................ 87 
14.4  Exclusion of Women, Minorities, and Ch ildren (Special Populations)  .................... 89 
DMID #[ADDRESS_1262783] 2019  
 
  
 
DMID/NIAID/NIH           [ADDRESS_1262784] Keepi[INVESTIGATOR_007]  ................................ ................................ ..................... 92 
15.1  Data Management Responsibilities ................................ ................................ ........... 92 
15.2  Data Capture Methods  ................................ ................................ .............................. 92 
15.3  Types of Data  ................................ ................................ ................................ ............ 93 
15.4  Timing/Reports  ................................ ................................ ................................ ......... 93 
15.5  Study Records Retention ................................ ................................ ........................... 93 
15.6  Protocol Deviations  ................................ ................................ ................................ ...94 
16 Publication Policy  ................................ ................................ ................................ ................. 95 
17 Literature References  ................................ ................................ ................................ ............ 97 
18 Supplements/Appendices  ................................ ................................ ................................ ......99 
Appendix A: Schedule of Events  ................................ ................................ ........................ 100 
Appendix B: Acceptable Ranges of Screening Laboratory Measurements  ........................ 103 
 
 
  
DMID #[ADDRESS_1262785] 2019  
 
  
 
DMID/NIAID/NIH           [ADDRESS_1262786] OF TABLES  
Table 1: Treatment Arms  ................................ ................................ ................................ ..............  31 
Table 2: Blood Volume (mL) – All Treatment Arms  ................................ ................................ ... 62 
Table 3:  Local (Injection Site) Reactogenicity Grading  ................................ ..............................  67 
Table 4:  Local (Injection Site) Reactogenicity Measurements  ................................ ....................  68 
Table 5: Subjective Systemic Reactogenicity Grading  ................................ ................................ . 68 
Table 6: Quantitative Systemic Reactogenicity Grading  ................................ ..............................  69 
Table 7: Blood Pressure and Pulse Grading  ................................ ................................ .................  69 
Table 8:  Clinical Screening & Safety Laboratory Adverse Event Grading (Hematology)  .........  70 
Table 9: Clinical Screening & Safety Laboratory Adverse Event Grading (Chemistry)  .............  70 
Table 10: Probability of Observing an Adverse Event for Various Event Rates  ..........................  81 
  
DMID #[ADDRESS_1262787] 2019  
 
  
 
DMID/NIAID/NIH           [ADDRESS_1262788] OF FIGURES  
Figure 1: Schematic of Study Design  ................................ ................................ ...........................  17 
 
DMID #[ADDRESS_1262789] 2019  
 
  
 
DMID/NIAID/NIH           [ADDRESS_1262790] OF ABBREVIATIONS  
AE Adverse Event/Adverse Experience  
ALT  Alanine Aminotransferase Test  
ANC  Absolute Neutrophil Count  
ANDV  Andes Virus  
BUN  Blood Urea Nitrogen  
CMS  Clinical Materials Services  
CFR  Code of Federal Regulations  
CRF  Case Report Form  
DHHS  Department of Health and Human Services  
DMID  Division of Microbiology and Infectious Diseases, NIAID, NIH,  
eCRF  Electronic Case Report Form  
EDCSM Electronic Data Capture  System  
FDA  Food and Drug Administration  
FWA  Federalwide Assurance  
GCP  Good Clinical Practice  
HBsAg  Hepatitis B Surface Antigen  
HCPS  Hantavirus Cardio/Pulmonary Syndrome  
HCV  Hepatitis C Virus  
HFRS Hemorrhagic Fever with Renal Syndrome  
Hgb Hemoglobin  
HgbA1C  Hemoglobin A1C  
HIPAA  Health Insurance Portability and Accountability Act  
HIV Human Immunodeficiency Virus  
HLA  Human Leukocyte Antigen  
HPS Hantavirus Cardio/Pulmonary Syndrome  
HTNV  Hantaan Virus  
ICF Informed Consent Form  
ICH International Conference on Harmonisation  
ICMJE  International Committee of Medical Journal Editors  
ICS Intracellular Staining  
IND Investigational New Drug Application  
IRB Institutional Review Board  
ISM Independent Safety Monitor  
LPS Lymphoproliferation Assa y 
DMID #[ADDRESS_1262791] 2019  
 
  
 
DMID/NIAID/NIH           11 
CONFIDENTIAL  
 MedDRA Medical Dictionary for Regulatory Activities  
MOP  Manual of Procedures  
N Number (typi[INVESTIGATOR_19737])  
NDA  New Drug Application  
NIAID  National Institute of Allergy and Infectious Diseases, NIH, 
DHHS  
NIH National Institutes of Health  
OHRP  Office for Human Research Protections  
PHI Protected Health Information  
PI [INVESTIGATOR_900571] D elivery  
PRNT  Plaque Reduction Neutralization Test 
PsVNA  Pseudovirion Neutralization Assay 
PUUV  Puumala  Virus  
QA Quality Assurance  
QC Quality Control  
SAE  Serious Adverse Event/Serious Adverse Experience  
SDCC  Statistical and Data Coordinating Center  
SMC  Safety Monitoring Committee  
SOP Standard Operating Procedure  
US [LOCATION_002]  
[LOCATION_003]MRI ID Unites States Army Medical Research Institute of Infectious 
Diseases  
WBC  White Blood Cell  
DMID #[ADDRESS_1262792] 2019  
 
  
 
DMID/NIAID/NIH           12 
CONFIDENTIAL  
 PROTOCOL SUMMARY  
Title:    A Phase I , Randomized, Placebo Controlled, Double -blind, Dose E scalation trial 
to Evaluate the Safety and Immunogenicity of an Andes Virus DNA Vaccine for 
the Prevention of Hantavirus Pulmonary Synd rome Using the PharmaJet Stratis® 
Needle -Free Injection System  in Normal Healthy Adults  
Phase:  I 
Population:  48 male s and non -pregnant females, 18 -49 years old, inclusive, who are in good 
health and meet all eligibility criteria  
Number of 
Sites:  One Vaccine and Treatment Evaluation Unit (VTEU) site  
Study 
Duration:  Approximately [ADDRESS_1262793] 
Participation 
Duration:  Approximately 12 months  
Description 
of Agent or 
Intervention:  Andes virus (ANDV) DNA vaccine , constructed  from recombinant gene 
segments , plasmid pWRG/AND -M (opt2) , was developed by [CONTACT_900597], US Army Medical Research Institute of Infectious Diseases 
and manufactured by [CONTACT_900598] (Fargo, ND).  ANDV DNA vaccine will be 
administered by [CONTACT_900599] ® Needle -Free Injection  System  in a 3 or 4 
dose regimen on Day s 1, 29, 57 and 169 at two doses, 2 or 4 mg . The placebo will 
be normal saline (0.9% Sodium Chloride, USP).  
Objectives : 
 Primary:  
• Assess  the safety and reactogenicity of the ANDV DNA vaccine by [CONTACT_900600]® 
Needle -Free Injection system  in normal, healthy adults.  
Secondary:  
DMID #[ADDRESS_1262794] 2019  
 
  
 
DMID/NIAID/NIH           13 
CONFIDENTIAL  
 • Assess the immunogenicity of the ANDV DNA vaccine by [CONTACT_900601] . 
Exploratory:  
• Assess c ellular immune response to ANDV DNA vaccine  by [CONTACT_900602] . 
• Assess immunogenicity of the ANDV DNA vaccine by [CONTACT_900603].  
Outcome 
Measures:  Primary:  
• Occurrence  of vaccine -related Serious Adverse Events ( SAEs ) through 
approximately [ADDRESS_1262795] vaccination.  
• Occurrence  of vaccine -related unsolicited Adverse Events ( AEs) through [ADDRESS_1262796] vaccination.  
• Occurrence of Serious Adverse Events ( SAEs ) through approximately [ADDRESS_1262797] vaccination.  
• Occurrence  of unsolicited Adverse Events ( AEs) through [ADDRESS_1262798] 
vaccination.  
• Occurrence  of solicited local and systemic AEs through  7 days after each 
study vaccination.  
• Occurrence  of clinical safety laboratory AEs through  7 days after each study 
vaccination.  
Secondary:  
• Incidence of an ANDV -specific titer of ≥ 20 on Day 57  (3 dose regimen) , Day 
85 (4 dose regimen)  and Day 197  (3 and 4 dose regimen)  as measured by:  
o Plaque reduction neutralization titers  
o Pseudovirion neutralization titers  
• Incidence of seroconversion (defined as a post-vaccination ANDV -specific 
titer ≥40 if baseline  titer <20 or a min imum four -fold rise compared to 
baseline  if baseline  titer ≥20 ) on Day 57 (3 dose regimen), Day 85 (4 dose 
regimen) and Day 197 (3 and 4 dose regimen) as measured by:  
[CONTACT_122830] #[ADDRESS_1262799] 2019  
 
  
 
DMID/NIAID/NIH           14 
CONFIDENTIAL  
 o Plaque reduction neutralization titers  
o Pseudovirion neutralization titers  
• Geometric mean titer (G MT) of neutralizing antibodies to ANDV on Day 57  
(3 dose regimen) , Day 85  (4 dose regimen)  and Day 197  (3 and 4 dose 
regimen)  as compared to baseline (Day 1) titer and measured by:  
o Plaque reduction neutralization titers  
o Pseudovirion neutralization titers  
Exploratory:  
• Incidence of a >[ADDRESS_1262800] deviation increase in  ANDV -specific, cytokine -
secreting CD4+ and CD8+ cells  on Day 29 (3 and 4 dos e regimen) , Day 57 (3 
dose regimen), Day 85 (4 dose regimen) , Day 169  (3 and 4 dos e regimen) , and 
Day 197  (3 and 4 dos e regimen) compared to baseline (Day 1) as measured  by 
[CONTACT_1603]-based intracellular staining (ICS).  
• Incidence of a >[ADDRESS_1262801] deviation  increase  in ANDV -specific  CD4+ and 
CD8+ cells on Day 29 (3 and 4 dos e regimen) , Day 57 (3  dose regimen), Day 
85 (4 dose regimen) , Day 169  (3 and 4 dos e regimen) , and Day 197  (3 and 4 
dose regimen) compared to baseline (Day 1) as measured by  a 
lympho proliferation assay (LPA ). 
• Incidence of an ANDV -specific titer of ≥ 20 at additiona l time points as 
measured by:  
o Pseudovirion neutralization titers  
o Plaque reduction neutralization titers  
Description 
of Study 
Design:  This is a  Phase 1, randomized, placebo controlled, double -blind, dose escalation 
trial of 48 males and non -pregnant females, 18 -49 years old, inclusive, who are in 
good health and meet all eligibility criteria. This trial is designed to assess the 
safety , reactogenicity  and immunogenicity of an A NDV  DNA vaccine for the 
preven tion of Hantavirus Pulmonary Syndrome  (HPS) . ANDV DNA vaccine or 
placebo will be administered using the PharmaJet Stratis ® Needle -Free Injection  
System . Subjects assigned to the 3 dose regimen will receive ANDV DNA 
vaccine on Days 1, 29 and 169, and placebo on Day 57. Subjects assigned to the  4 
dose regimen  will receive ANDV DNA on Days 1, 29, 57 and 169 . Two doses  
(i.e., 2 or 4 mg) of ANDV DNA vaccine will be evaluated .  
DMID #[ADDRESS_1262802] 2019  
 
  
 
DMID/NIAID/NIH           [ADDRESS_1262803] s will be screened for Human Immunodeficiency Virus (HIV)  type 1 & 2  
antibody , Hepatitis C Virus (HCV) antibody, and Surface Antigen for Hepatitis B 
Virus (HBsAg) prior to enrollment.  
The first [ADDRESS_1262804] will receive study  
vaccine in an open -label  manner . The two  sentinels will be followed for safe ty 
through Day 8 (laboratory and solicited/unsolicited AEs) and if no pre -defined 
halting rules are met and no safety concerns are identified, enrollment of the 22 
remaining subjects in Cohort s 1 and 2 will proceed, otherwise a Safety 
Monitoring Committee (SMC) meeting will be held to conduct an electronic 
review (E -Review) of clinical and laboratory safety and reactogenicity data. 
While safety data is being evaluated for the sentinel subjects, no new subjects will 
be enrolled, but screening may continue.  
The 22 non -sentinel subjects in Cohort s 1/2 will be randomized  in a 9:2:9:2 ratio  
(Treatment Arms 1b:1c:2b:2c ) to receive  either placebo or study vaccine (at a 
dose of 2 mg ) in a [ADDRESS_1262805] second vaccination for all 24 
subjects in Cohort s 1 and 2 and provide recommendations to proceed to Cohort s 3 
and 4 or, if necessary, modify the protocol before proceeding . While safety data is 
being evaluated by [CONTACT_4484],  no new subjects will be enrolled , but s creening for 
Cohort s 3 and 4 and vaccination of the remaining doses in Cohort s 1 and 2 may 
continue.  
The 24 participants  in Cohort s 3 and 4 will follow the same schedu le as outlined 
for Cohort s 1 and 2 above. Sentinel  subjects will receive 4 mg of study vaccine 
open label in a 3 or 4 dose regimen and be followed for safety through Day 8. T he 
remaining 22  non-sentinel  subjects in Cohort s 3 and 4 will be randomized  in a 
DMID #[ADDRESS_1262806] 2019  
 
  
 
DMID/NIAID/NIH           16 
CONFIDENTIAL  
 9:2:9:2 ratio (Treatment Arms 3b:3c:4b:4c ) to receive placebo or study vaccine at 
a dose of [ADDRESS_1262807] 
study vaccination will be collected. Clinical safety labs will be collected on Day 1  
and 169, and 7 days after each vaccination; if labs are abnormal, they will be 
repeated  at the next scheduled visit (sooner if medically indicated)  and followed 
to normal or s tabilization.  
Immunogenicity testing will include evaluation of the cellular immune response 
to ANDV peptide pool s and assessment of humoral immune response as 
measured by [CONTACT_900604] (PsVNA) and by [CONTACT_900605] (PRNT). PsVNA will be measured prior to 
study vaccination (Day 1) and approximately on Days 29, 57, 85, 169, 197, 253, 
and 337. ANDV PRNT  will be measured im mediately prior to study vaccination 
(Day 1) and approximately  on Days 57, 85, 169  and 197. PBMCs to be used in 
the cellular assays , flow-based ICS and LPA , will be obtained at day 1 , 29, 57, 85 , 
169 and 197.  Blood will also be obtained at Days 85, 197 and  337 (PBMCs) for 
potential future exploratory assays. The duration of this trial for each subject will 
be approximately 12 months.  
Estimated 
Time to 
Complete 
Enrollment:  Approximately 6 months  
  
DMID #[ADDRESS_1262808] 2019  
 
  
 
DMID/NIAID/NIH           17 
CONFIDENTIAL  
  
   
  
 
 
 
 
 
 
 
 
 
 
 
 Figure 1: Schematic of Study Design  
Consent & Assess Eligibility  
Planned Enrollment: Total N=48 Subjects  
Males and non -pregnant females, 18 to 49 years old, inclusive  
 
Cohorts 1  and 2 sentinel subjects, dose 1 (n=2). 
Continue recruitment and screening  
Randomization and Vaccination of remaining subjects (Cohorts 
1and 2, 2mg Dose)  
 
Administer ANDV vaccine or placebo per Subject 
Assignment on Day [ADDRESS_1262809] second 
vaccination, proceed with Cohort 3  and 4 
 
Assessment of   Final 
Outcome Measures  
Randomized 9:2:9:2  
1b. Vaccine 3 -dose regimen : 1c..Placebo: 2b . Vaccine 4 -dose regimen: 2c placebo  
ine: 4-dose regimen: 2c: placebo  
Randomization and Vaccination of remaining subjects (Cohorts 3  
and 4, 4mg Dose)  
Cohort 3  and4 sentinel subjects, dose 1 (n=2). 
Continue recruitment and screening  
Administer ANDV vaccine or placebo 
per Subject Assignment on Day 1  
Follow -up for Safety, Reactogenicity,  and 
Immunogenicity  
Randomized 9:2 :9:2 
3b. Vaccine  3-dose regimen : 3c. Placebo : 4b. Vaccine 4 -dose regimen: 4c. placebo  
DMID #[ADDRESS_1262810] 2019  
 
  
 
DMID/NIAID/NIH           18 
CONFIDENTIAL  
 1 KEY ROLES  
Individuals:  Protocol Champi[INVESTIGATOR_2394]:    
Gabriele Feolo, RN,MSN  
Virology Branch  
NIAID, NIH   
 Principal Investigator:    
[INVESTIGATOR_900570], MD  
Cincinnati Children’s Hospi[INVESTIGATOR_900572] :  
Kay M. Tomashek, MD, MPH, DTM  
Division of Microbiology and Infectious Diseases  
NIAID, NIH  
 Medical Monitor:  
Jorge Mejia -Galvis , MD,  
Office of Clinical Research Affairs  
Division of Microbiology and Infectious Diseases  
National Institute of Allergy and Infectious Diseases  
National Ins titutes of Health  
Institutions:  Cincinnati Children’s Hospi[INVESTIGATOR_900573] (Clinical) 
Laboratory:  Cincinnati Children’s Hospi[INVESTIGATOR_900574]:  The Singh Laboratory  
Karnail Singh, PhD  
ANDV Neutralization 
Assays Laboratory:  [LOCATION_003]MRI ID  
Jay Hooper, PhD 
Study Agent Repository:  Fisher BioServices  
c/o DMID Clinical Materials Services  Contract  
DMID #[ADDRESS_1262811] 2019  
 
  
 
DMID/NIAID/NIH           19 
CONFIDENTIAL  
 Statistical and Data 
Coordinating Center  The Emmes Corporation  
Safety and 
Pharmacovigilance 
Contractor:  DMID Pharmacovigilance Group  
Clinical Research Operations and Management Support 
(CROMS)  
[ADDRESS_1262812]., Suite 650  
Bethesda, MD [ZIP_CODE]  
SAE Hot Line: 1 -[PHONE_889] (US)  
SAE Fax: 800 -275-7619 (US)  
SAE Email: [EMAIL_1393]  
 
DMID #[ADDRESS_1262813] 2019  
 
  
 
DMID/NIAID/NIH           20 
CONFIDENTIAL  
 2 BACKGROUND INFORMATION AND SCIENTIFIC 
RATIONALE  
2.1 Background Information  
Hantaviruses are members of the Bunyaviridae family and are found worldwide. Hantaviruses 
are negative -sense, single -stranded RNA viruses with three segments:  small (S), medium (M), 
and large (L). The M -segment encodes the envel ope glycoproteins (Gn and Gc). Over [ADDRESS_1262814] vascular endothelial cells in humans causing dysfunction and 
increased vascular permeability2. The two primary disease  presentatio ns in humans are due to 
vascular leak age; hemorrhagic fever with renal syndrome (HFRS) and hantavirus cardio/  
pulmonary syndrome (HCPS or HPS). H PS was first described in 1993 in the southwestern 
[LOCATION_002], with subsequent identification of Sin Nombre virus (SNV) as the causative agent. 
HPS typi[INVESTIGATOR_560468] a non -specific viral illness with cough, fever, chills, nausea/vomiting, 
diarrhea, myalgia  and/or headache for 3 -6 days, followed by [CONTACT_900606]3. HFRS is mor e common (>20,000 cases/year), and is generally limited to Asia, 
Europe, Scandinavia, and Russia . HFRS  presents with similar prodromal symptoms, and less 
commonly leads to hypotension, shock and acute renal failure4,5. 
 
In South America , the Andes virus (ANDV) is the predominant cause of HPS  with the majority 
of cases occurring in Brazil, Chile and Argentina; there have been  a few case reports from  
Bolivia, Paraguay and Uruguay .6-8 HPS due to ANDV is primarily a zoonotic disease in huma ns, 
spread via rodent excreta. While rodents, shrews, moles and bats can all be reservoir hosts for 
hantaviruses, the long -tailed rat ( Oligoryzomys longicaudatus ) is the host of ANDV and the deer 
mouse ( Peromyscus maniculatus ) remains the reservoir of the SNV2. Both are relatively 
common rodents and can be trapped in the wild. Unlike the other known hantaviru ses, ANDV 
remains the only one with persuasive evidence of person -to-person transmission7,9. 
 
While HPS is relatively uncommon (approximately 600 US cases & 4,000 South American from 
1993 -2012/13), it remains a serious infection, with m ortality rates due to ANDV infection of 35 -
40%, despi[INVESTIGATOR_900575]3,10,11. Additionally, there is no vaccine or effective  
therapy for HPS and treatment remains supportive and symptomatic. In the [LOCATION_002], due to 
the relative infrequency of hantavirus in general and HPS in particular,  seroprevalence of IgG 
antibodies to hantaviruses are uncommon . Among indiv iduals t ested in a Baltimore, MD  area 
study12,13 only 0.7  – 2.1% of the group had detectable serum antibodies to Hantaan, Seoul or 
DMID #[ADDRESS_1262815] 2019  
 
  
 
DMID/NIAID/NIH           [ADDRESS_1262816] been developed.4 A phase 1 clinical trial of  Hantaan Virus  
(HTNV ) and Puumala  Virus ( PUUV ) DNA vaccines reported neutralizing antibodies of 30% and 
40% to HTNV and PUUV, respectively.4 In the combined vaccine group, 56% developed 
neutralizing antibodies to one or both viruses .[ADDRESS_1262817] em, and administering 2 doses of vaccine , seroconversion was increased to 
64% and 75% to HTNV and PUUV, respectively .1 Currently , there is an ongoing phase 2a trial 
comparing two different dosing schedules of a mixed HTNV/PUUV DNA vaccine administered 
via IM -EP (clinicaltrials.gov, [STUDY_ID_REMOVED]) as well as a phase 1 tria l evaluating HTNV and 
PUUV DNA vaccines delivered by [CONTACT_900599]® Needle -Free Injection System  
(clinicaltrials.gov, [STUDY_ID_REMOVED]).   
 
In order to develop a pan -hantavirus DNA vaccine, an ANDV vaccine has been developed using 
the same strategy and plasmid backbone as the HTNV and PUUV DNA vaccines. The 
development of the HTNV DNA, PUUV DNA, and the ANDV DNA vaccines from the same 
plasmid backbone, combined with the immunogenicity results of the previous hantavirus DNA 
vaccines, provides the rationale for evaluating the ANDV DNA vaccine administered by [CONTACT_900607]® Needle -Free Injection System  in humans. The plasmid, pWRG/AND -M 
(opt2), which is the active ingredient for the ANDV DNA vaccine, was constructed on a well -
characterized plasmid backbone, pWRG7077, and synthesized elements of the ANDV DNA 
genome. The optimized ANDV M gene encodes viral GnGc envelope glycoproteins that hav e 
been shown to be the targets of neutralizing antibodies .14 The DNA vaccine was developed by 
[CONTACT_900608], US Arm y Medical Research Institute of Infectious 
Diseases ([LOCATION_003]MRIID; Fort Detrick, Maryland), and the final vaccine was manufactured by 
[CONTACT_900598] (Fargo, ND). The proposed trial would be a first in man vaccine trial for the prevention 
of HPS.  
2.1.1 Safety/Toxicology of  similar vaccines  
The plasmid vector backbone, pWRG7077, has been used in several DNA vaccines, including 
HTNV and PUUV DNA vaccines and a Venezuelan  Equine Encephalitis (VEE) DNA vaccine.  
In the VEE study, 41 subjects received one or more immunizations a nd there were no serious or 
unanticipated safety concerns identified.15 There were 6 74 AEs recorded for all subjects over the 
DMID #[ADDRESS_1262818] 2019  
 
  
 
DMID/NIAID/NIH           22 
CONFIDENTIAL  
 course of the study, the majority were local with resolution within 24 hours. Systemic AEs were 
also generally mild and transient; the only Grade [ADDRESS_1262819] involved 3 cohorts of volunteers 
vaccinated with a DNA vaccine expressing M segments of HTNV and/or PUUV delivered via 
disposable gene gun devices  (a.k.a. particle mediated epi[INVESTIGATOR_900576], PMED ). Among the [ADDRESS_1262820] withdrew due to adverse events .4 Injection site pain was 
noted following 48 -56% of doses and injection site tenderness following 79 -89% of doses. All 
injection site pain was mild and moderate tenderness was document ed only following the 3rd 
dose in 7% of subjects. The most common systemic AEs were fatigue, malaise, myalgia  and, 
headache . Less common was oropharyngeal pain  noted in [ADDRESS_1262821] one immunization with HTNV 
DNA, PUUV DNA or mixture of both via intramuscular electroporation (IM -EP) was recently 
published .[ADDRESS_1262822] 
common solicited local AE was pain at the injection site  which occurred  in 28/[ADDRESS_1262823] as the current pro posal (pWRG/AND -
M (opt2)), demonstrated that a combined ANDV DNA and SNV DNA vaccine elicited 
neutralizing antibodies in rabbits and nonhuman primates17. In this study, significantly higher 
neutralizing  titers were seen using a disposable syringe jet injection (DSJI)  system as compared 
to needle/syringe delivery; anti -ANDV PRNT50 geometric mean titers (GMTs) were 349 versus 
42 (p = 0.01). No safety issues or adverse events were reported.  
 
DMID #[ADDRESS_1262824] 2019  
 
  
 
DMID/NIAID/NIH           [ADDRESS_1262825] or delivery method . 
2.1.3 Vaccine Delivery System  
Historically, due to poor uptake of the DNA following injection, DNA vaccination has failed to 
raise a strong immun e response in humans .20 This has led to a progression of delivery systems to 
improved immunogen icity. The gene gun uses gold -coated DNA delivered with helium pressure 
and has shown  promise. Electroporation (EP) was subsequently developed and it applies a  
current over cell membranes to increase cellular uptake. EP has been shown to increase uptake 
and immune response in humans, but can require a somewhat more complex apparatus21. DSJI 
systems have also been used successfully to administer DNA vaccines with good tolerability and 
effect  (Hooper et a l., unpublished data) .[ADDRESS_1262826] 60 years, with estimates of hundreds of millions of doses 
delivered, including ANDV DNA vaccine delivery in nonhuman primates, as noted above17. The 
PharmaJet Stratis® Needle -Free Injection System  is a US Food and Drug Administration ( FDA ) 
510k -cleared for administering FDA - approved medicines and is the proposed delivery system in 
this trial .[ADDRESS_1262827] 
DMID #[ADDRESS_1262828] 2019  
 
  
 
DMID/NIAID/NIH           24 
CONFIDENTIAL  
 since shown that by [CONTACT_44579] a plasmid, expressing a viral antigen under the control of a 
promoter, an immune response to the viral antigen could be detected .23 The current hantavirus 
DNA vaccine candidates utilize recombinant glycoprotein gene segments that are then subcloned 
into a plasmid backbone (pWRG7077). Given t hat the HTNV DNA, PUUV DNA, and ANDV 
DNA vaccines are all designed on the same plasmid backbone, the results of these ongoing 
clinical trials coupled with the immunogenicity of these DNA vaccines in humans and animals, 
provide the rationale for evaluating the ANDV DNA vaccine administered by [CONTACT_900609]® Needle -Free Injection System  in humans.  
2.3 Potential Risks and Benefits  
2.3.1 Potential Risks  
The potential risks of this trial are those associated with having blood drawn , intramuscular  
injections  (IM) , and possible reactions to the experimental ANDV v accine.  There may  be 
potential risk related to breach of confidentiality, as well as o ther unknown risks, discomforts, or 
side effects . 
 
The ANDV  vaccine to be used in this clinical trial h as never been administered to humans. It is 
administered intramuscul arly and it is possible that vaccination may cause pain, tenderness, 
erythema (redness), induration (hardness/swelling), bruising and skin discoloration at the 
injection site. The vaccine may also cause systemic reactions such as fever, feverishness (chills, 
shivering, sweating), fatigue (tiredness), malaise (general unwell feeling), myalgia (body 
aches/muscular pain), nausea, dizziness , and headache.  A less likely symptom is tachypnea 
(rapid breathing).  In addition, vaccines can cause a severe allergic reaction.  Such reactions are 
rare and would happen within a few minutes to a few hours after vaccination. Signs of a severe 
allergic reaction can include rash or hives, swelling of the face a nd throat, difficulty breathing, a 
fast heartbeat, dizziness, and weakness.   
 
Based on the results of preclinical and clinical studies performed using DNA vaccines with the 
same plasmid backbone (pWRG7077), the likelihood of DNA integration or production of anti - 
DNA antibodies for the ANDV DNA vaccine is minimal.24,[ADDRESS_1262829] agree to practice effective contraception for a minimum of 30 days prior to study 
DMID #[ADDRESS_1262830] 2019  
 
  
 
DMID/NIAID/NIH           [ADDRESS_1262831] agree to no t donate eggs (ova, 
oocytes) and male subject agrees not to donate sperm from the start of screening period until at 
least [ADDRESS_1262832] lie down and elevate his/her legs. Bruising at the blood draw site 
may occur, but can be prevented or lessened by [CONTACT_119911] a 
few minutes after the blood is taken. Drawing blood may al so cause infection. The use of aseptic 
(sterile) technique will make infection at the site where blood will be drawn extremely unlikely.  
 
An IM injection may cause transient discomfort and fainting. Giving an IM injection may also 
predispose a subject to i nfection. However, the use of sterile technique will make an infection at 
the injection site extremely unlikely .  The Pharmajet needle free delivery of vaccines has been 
associated with more local reactogenicity (e.g. pain, tenderness itching, redness or s welling) that 
was mild or moderate in nature than was observed with needle and syringe injections of 
vaccines.  There were no differences in systemic adverse events  
  
Subjects will be asked to provide personal health information (PHI). All attempts will be made to 
keep this PHI confidential within the limits of the law. However, there is a chance that 
unauthorized persons will see the subjects’ PHI. All study records will be kept in a locked file 
cabinet or maintained in a locked room at the VTEU sit e. Electronic files will be password -
protected. Only people who are involved in the conduct, oversight, monitoring, or auditing of 
this trial will be allowed access to the PHI that is collected. Any publications from this trial will 
not use information tha t will identify subjects by [CONTACT_2300]. Organizations that may inspect and/or 
copy research records maintained at the site for quality assurance and data analysis include 
groups such as the local Institutional Review Board (IRB), NIAID  and their designees , 
[LOCATION_003]MR IID and FDA.  
 
There may be other risks, discomforts, or side effects that are unknown at this time.   
DMID #[ADDRESS_1262833] 2019  
 
  
 
DMID/NIAID/NIH           [ADDRESS_1262834] HPS due to ANDV and/or that 
vaccination  will result in protection from  HPS caused by [CONTACT_900610] . The duration  of any such 
protection is currently unknown.  
DMID #[ADDRESS_1262835] 2019  
 
  
 
DMID/NIAID/NIH           27 
CONFIDENTIAL  
 3 OBJECTIVES  
3.1 Study Objectives  
3.1.1 Primary Study Objective  
• Assess the safety and reactogenicity of the ANDV DNA vaccine by [CONTACT_900611]® Needle -Free Injection system 
in normal, healthy adults.  
3.1.2 Secondary Study Objectives  
• Assess the immunogenicity of the ANDV DNA  vaccine by [CONTACT_900612].  
3.1.3 Exploratory Study Objectives  
• Assess cellular immune response to ANDV DNA vaccine by [CONTACT_900613]. 
• Assess immunogenicity of the ANDV DNA vaccine by [CONTACT_900614].  
3.2 Study Outcome Measures  
3.2.1 Primary Outcome Measures  
• Occurrence of vaccine -related Serious Adverse Events (SAEs) through approximately [ADDRESS_1262836] vaccination.  
• Occurrence of vaccine -related unsolicited Adverse Events (AEs) through [ADDRESS_1262837] 
vaccination.   
• Occurrence of Serious Adverse Events ( SAEs ) through approximately [ADDRESS_1262838] 
vaccination.  
• Occurrence  of unsolicited Adverse Events ( AEs) through [ADDRESS_1262839] vaccination.  
• Occurrence of solicited local and systemic AEs through 7 days after each study vaccination.  
• Occurrence of clinical safety laboratory AEs through 7 days after each study vaccination.  
DMID #[ADDRESS_1262840] 2019  
 
  
 
DMID/NIAID/NIH           28 
CONFIDENTIAL  
 3.2.2 Secondary Outcome Measures  
• Incidence of an ANDV -specific titer of ≥ 20 o n Day 57 (3 dose regimen), Day 85 (4 dose 
regimen) and Day 197 (3 and 4 dose regimen) as measured by:  
o Plaque reduction neutralization titers  
o Pseudovirion neutralization titers  
• Incidence of seroconversion (defined as a post -vaccination ANDV -specific titer ≥ 40 if 
baseline titer <20 or a minimum four -fold rise compared to baseline if baseline titer ≥20) on 
Day 57 (3 dose regimen), Day 85 (4 dose regimen) and Day 197 (3 and 4 dose regimen) as 
measured by:  
o Plaque reduction neutralization titers  
o Pseudovirion neut ralization titers  
• Geometric mean titer (GMT) of neutralizing antibodies to ANDV on Day 57 (3 dose 
regimen), Day 85 (4 dose regimen) and Day 197 (3 and 4 dose regimen) as compared to 
baseline (Day 1) titer and measured by:  
o Plaque reduction neutralization titers  
o Pseudovirion neutralization titers  
3.2.3 Exploratory Outcomes  
• Incidence of a >[ADDRESS_1262841] deviation increase in ANDV -specific, cytokine -secreting CD4+ 
and CD8+ cells on Day 29 (3 and 4 dose regimen), Day 57 (3 dose regimen), Day 85 (4 dose 
regimen), Day 169 (3 and 4 dose regimen) and Day 197 (3 and 4 dose regimen) compared to 
baseline (Day  1) as measured by [CONTACT_1603] -based ICS . 
• Incidence of a >[ADDRESS_1262842] deviation increase in ANDV -specific CD4+ and CD8+ cells on 
Day 29 (3 and 4 dose regimen), Day 57 (3 dose regimen), Day 85 (4 dose regimen), Day 169 
(3 and 4 dose regimen) and Day 197  (3 and 4 dose regimen) compared to baseline (Day  1) as 
measured by a LPA . 
• Incidence of an ANDV -specific titer of ≥20 at additional time points as measured by:  
o Pseudovi rion neutralization titers  
o Plaque reduction neutralization titers  
DMID #[ADDRESS_1262843] 2019  
 
  
 
DMID/NIAID/NIH           29 
CONFIDENTIAL  
 4 STUDY DESIGN  
This is a Phase 1, randomized, placebo controlled, double -blind, dose escalation trial of 48 males 
and non -pregnant females, 18 -49 years old, inclusive, who are in good health a nd meet all 
eligibility criteria. This trial is designed to assess the safety, reactogenicity and immunogenicity 
of an ANDV DNA vaccine for the prevention of Hantavirus Pulmonary Syndrome (HPS). 
ANDV DNA vaccine or placebo will be administered using  the PharmaJet Stratis ® Needle -Free 
Injection  System . Subjects assigned to the 3 dose regimen will receive ANDV DNA vaccine on 
Days 1, 29 and 169, and placebo on Day 57. Subjects assigned to the 4 dose regimen will receive 
ANDV DNA on Days 1, 29, 57 and 169.  Two doses (i.e., 2 or 4 mg) of ANDV DNA vaccine 
will be evaluated .  
Potential subjects will be screened by [CONTACT_969], physical exam, vital signs, and clinical laboratory 
tests including white blood cells (WBC) , hemoglobin (Hgb), platelet count, absolute neutroph il 
count (ANC) , Hemoglobin A1C ( HgbA1C ), total bilirubin, alanine aminotransferase (ALT), 
sodium, potassium, and creatinine. Blood urea nitrogen (BUN) will be obtained only if creatinine 
is above the normal range. Height and weight will be obtained. A urin alysis will be done for 
urine protein and drug screening for opi[INVESTIGATOR_858]. Potential f emale subjects of childbearing potential 
will have a serum pregnancy test. In addition, potential subjects will be screened for HIV – 1/[ADDRESS_1262844] -in-human Phase 1 study. Sentinel subjects will receive 2 mg of study vaccine in an 
open label  manner  but wi ll be randomized and blinded to the dose regimen . Subjects randomized  
to the 3 dose regimen (Cohort 1) will receive ANDV DNA vaccine on Days 1, 29 and 169, and 
placebo on Day 57. Subjects randomized  to the 4 dose regimen  (Cohort 2)  will receive ANDV 
DNA o n Days 1, 29, [ADDRESS_1262845] will 
receive study vaccine in an open -label  manner . The two sentinels w ill be followed for safety 
through Day 8 (laboratory and solicited/unsolicited AEs) and if no pre -defined halting rules are 
met and no safety concerns are identified, enrollment of the 22 remaining subjects in Cohort 1  
and 2 will proceed, otherwise a Safet y Monitoring Committee (SMC) meeting will be held to 
conduct an electronic review (E -Review) of clinical and laboratory safety and reactogenicity 
data. While safety data is being evaluated for the sentinel subjects, no new subjects will be 
enrolled, but sc reening may continue.  
The 22 non -sentinel subjects in Cohort s 1 and 2 will be randomized in a 9:2:9:2 ratio (Treatment 
Arms 1b:1c:2b:2c) to receive either study vaccine  (at a dose of 2  mg) or placebo in a 3 or 4 dose 
DMID #[ADDRESS_1262846] 2019  
 
  
 
DMID/NIAID/NIH           [ADDRESS_1262847] second vaccination for all 24 subjects in Cohort 1  and 2 and provide recommendations to 
proceed to Cohort 3  and 4 or, if necessary , modify the protocol before proceeding . While safety 
data is be ing evaluated by [CONTACT_4484], no new subjects will be enrolled, but screening for Cohort s 
3 and 4 and vaccination of the remaining doses in Cohort s 1 and 2 may continue.  
The 24 participants in Cohort s 3 and 4 will follow the same schedule as outlined for Coho rts 
1and 2 above. Sentinel subjects will be randomized to a dose regimen and will  receive 4 mg of 
study vaccine open label and be followed for safety through Day 8. Subjects assigned to the 3 
dose regimen will receive ANDV DNA vaccine on Days 1, 29 and 169, and placebo on Day 57. 
Subjects assigned to the 4 dose regimen will receive ANDV DNA on Days 1, 29, 57 and 169 . 
The remaining 22 non -sentinel subjects in Cohort s 3 and 4 will be randomized in a 9:2:9:2 ratio  
(Treatment Arms 3b:3c:4b:4c ) to receive stu dy vaccine or placebo at a dose of 4 mg in a 3 or 4 
dose regimen, in double blind fashion.   
Doses 2 -4 for all treatment arms will be administered per the schedule outlined in the table 
below, assuming no halting rules are met.  
  
DMID #[ADDRESS_1262848] 2019  
 
  
 
DMID/NIAID/NIH           31 
CONFIDENTIAL  
 Table 1: Treatment Arms  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Cohort  Subjects 
Enrolled  Randomization/ 
Treatment 
Arm*# Day 1  Day 29  Day 57  Day 169  
Cohort 1  
2mg^ 12 1a*  
n=1  
Sentinel  ANDV 
DNA  ANDV 
DNA  Placebo  ANDV 
DNA  
1b# 
N=9 
ANDV DNA  ANDV 
DNA  ANDV 
DNA  Placebo  ANDV 
DNA  
1c# 
n=2 
Placebo  Placebo  Placebo  Placebo  Placebo  
Cohort 2  
2mg^ 12 2a*  
n=1  
Sentinel  ANDV 
DNA  ANDV 
DNA  ANDV 
DNA  ANDV 
DNA  
2b# 
N=9 
ANDV DNA  ANDV 
DNA  ANDV 
DNA  ANDV 
DNA  ANDV 
DNA  
2c# 
n=2 
Placebo  Placebo  Placebo  Placebo  Placebo  
Cohort 3  
4mg+ 
 12 3a*  
n=1  
Sentinel  ANDV 
DNA  ANDV 
DNA  Placebo  ANDV 
DNA  
3b# 
N=9 
ANDV DNA  ANDV 
DNA  ANDV 
DNA  Placebo  ANDV 
DNA  
3c# 
n=2 
Placebo  Placebo  Placebo  Placebo  Placebo  
Cohort 4  
4mg+ 
 12 4a*  
n=1  
Sentinel  ANDV 
DNA  ANDV 
DNA  ANDV 
DNA  ANDV 
DNA  
4b# 
N=9 
ANDV DNA  ANDV 
DNA  ANDV 
DNA  ANDV 
DNA  ANDV 
DNA  
4c# 
n=2 
Placebo  Placebo  Placebo  Placebo  Placebo  
TOTAL  48 subjects  
* All sentinel subjects and study personnel will be unblinded to dose and blinded to treatment 
schedule.  
# All non -sentinel subjects will be blinded to dose and treatment schedule.  
^  1mg ANDV DNA administered into the left and right deltoid  
+  2mg ANDV DNA administered into the right and left deltoid.  
DMID #[ADDRESS_1262849] 2019  
 
  
 
DMID/NIAID/NIH           [ADDRESS_1262850] and fourth vaccination 
days, clinical  safety laboratory tests will be collected pre -vaccination . Vaccine and/or placebo 
will then be administered by [CONTACT_900615] ® Needle -Free 
Injection  System , into both the  left and right deltoid muscle  one after another  or simultaneously . 
In this way, subjects will be blinded to cohort (i.e., dosage group) and treatment arm within a 
cohort.    
Subjects will be observed for [ADDRESS_1262851] study vaccination will be 
collected. Clinical safety labs will be collected on Days 1 and 169, and 7 days after each 
vaccination; if labs are outside the clinical laboratory reference range, they will be repeated at the 
next scheduled visit (sooner if medically indicated) and, followed to normal or stabilization.  
Immunogenicity testing will include evaluation of the cellular immune response to ANDV 
neutralizing  antibodies peptide pool and assessment of humoral immune response as measured 
by [CONTACT_900604] (PsVNA) and by [CONTACT_900610] P laque Reduction 
Neutralization Test (PRNT). PsVNA will be measured prior to study vaccination (Day 1) and 
approximately on Days 29, 57, 85, 169, 197, 253, and 337. PRNT will be measured immediately 
prior to study vaccination (Day 1) and approximately on Da ys 57, 85, 169 and 197. PBMCs to be 
used in the cellular assays (ICS+ LPA) will be obtained at day 1, 29, 57, 85, 169 and 197. Blood 
will also be obtained at Days 85, 197 and 337 (PBMCs) for potential future exploratory assays. 
The duration of this trial f or each subject will be approximately 12 months.  
For additional details on study procedures and evaluations by [CONTACT_319650]/days, see Appendix A: 
Schedule of Events . 
DMID #[ADDRESS_1262852] 2019  
 
  
 
DMID/NIAID/NIH           [ADDRESS_1262853] (IRB) will approve 
all materials prior to use.  
Subject Inclusion and Exclusion Criteria must be assessed by a study clinician licensed to make 
medical diagnoses and listed on the Form  FDA [ADDRESS_1262854] meet all of the following inclusion criteria:  
1. Provide written informed consent before initiation of any study procedures.  
2. Are able to understand and comply with planned study procedures and be available for all 
study visits/phone calls.  
3. Males or non -pregnant females ages 18 -49, inclusive.  
4. Are in good health  * 
* As determined by [CONTACT_900616], defined as those that have been present for at least [ADDRESS_1262855] 60 days  (no 
hospi[INVESTIGATOR_602], ER or urgent care for condition and no adverse symptoms that need medical 
intervention such as medication ch ange/supplemental oxygen) . This includes no change in chronic 
prescription medication, dose, or frequency as a result of deterioration of the chronic medical 
diagnosis or condition in the 60 days prior to enrollment. Any prescription change that is due to 
change of health care provider, insurance company, etc., or that is done for financial reasons, as 
long as in the same class of medication, will not be considered a deviation of this inclusion 
criterion. Any change in prescription medication due to improve ment of a disease outcome, as 
DMID #[ADDRESS_1262856] 2019  
 
  
 
DMID/NIAID/NIH           34 
CONFIDENTIAL  
 determined by [CONTACT_16541] [INVESTIGATOR_29353] -investigator, will not be considered 
a deviation of this inclusion criterion. Subjects may be on chronic or as needed (prn) medications 
if, in the opi[INVESTIGATOR_900577] -investigator, they pose no 
additional risk to subject safety or assessment of reactogenicity and immunogenicity and do not 
indicate a worsening of medical diagnosis or condition. Similarly, medication changes  subsequent 
to enrollment and study vaccination are acceptable provided there was no deterioration in the 
subject’s chronic medical condition that necessitated a medication change, and there is no 
additional risk to the subject or interference with the eva luation of responses to study vaccination. 
Note: Topi[INVESTIGATOR_2855], nasal, and inhaled medications ( apart from  steroids as outlined in the Subject 
Exclusion Criteria), herbals, vitamins, and supplements are permitted.  
5. Oral temperature is less than 100.0 °F (37.8oC). 
6. Pulse is 47 to 105 beats per minute (bpm), inclusive.  
7. Systolic blood pressure (BP) is 85 to 150mm Hg, inclusive.  
8. Diastolic blood pressure (BP) is [ADDRESS_1262857] acceptable screening laboratories*,** within 28  days prior to enrollment . 
* Refer to Appendix B for range of acceptable laboratory values . 
*  Screening laboratory values that are outside  acceptable  range but are thought to be due to an acute 
condition or due to laboratory error may be repeated once.  [see Manual of Procedures (MOP)]  
10. Urine protein screen is negative or trace . 
11. Drug screen for opi[INVESTIGATOR_319609].  
12. HgbA1C <6. 3% at screening.  
13. HIV – 1/2 antibody negative.  
14. HCV antibody negative.  
15. HBsAg  negative.  
16. Women of childbearing potential*, must be using an effective method of contraception** from 
[ADDRESS_1262858] study vaccination.  
*  Women of childbearing potential are defined as those who have not been  sterilized via tubal 
ligation, bilateral oophorectomy, hysterectomy, or successful Essure® placement (permanent, non -
surgical, non -hormonal sterilization) with history of documented rad iological confirmation test at 
least 90 days after the procedure  (or with use of another birth control method if history of 
confirmation test not confirmed) , AND are  still menstruating or  < [ADDRESS_1262859] menses if 
perimenoap ausal.  
** For this study, we define an effective contraceptive method as one that results in a failure rate of 
less than 1% per year when it is used consistently and correctly. This i ncludes, but is not limited to, 
DMID #[ADDRESS_1262860] 2019  
 
  
 
DMID/NIAID/NIH           35 
CONFIDENTIAL  
 non-male sexual relationships, abstinence from sexual interc ourse with a male partner,  monogamous 
relationship with a vasectomized partner, male condoms with the use of applied spermicide, 
intrauterine devices, NuvaRing®, and licensed hormonal methods such as implants, injectables or 
oral contraceptives (“the pi[INVESTIGATOR_4382]” ).   
17. Women of childbearing potential* must have a negative serum pregnancy test at screening 
and a negative urine pregnancy test within 24 hours prior to each study vaccination.  
* see definition  of women of childbearing potential above. 
18. Sexually active male  participants  whose partner is  a woman of childbearing potential* and 
has not had a vasectomy**  must agree not to f ather a child until [ADDRESS_1262861] 
vaccination***.  
* see definition  of women of childbearing potential above.  
** perform ed > 1 year prior to screening 
***must agree to use a barrier method of birth control e.g., either condom with spermicidal  
foam/gel/film/cream or partner reports usage of  occlusive cap (diaphragm or cervical/vault caps) 
with spermicidal foam/gel/film/cream/suppository.   
19. Women agree to not donate eggs (ova, oocytes) and male subject agrees not to donate sperm 
from the start of screening onwards until at least [ADDRESS_1262862] not meet any of the following exclusion 
criteria:  
1. Women who are pregnant , planning to become pregnant  or lactating*. 
* Includes breastfeeding or planning to breastfeed at any given time from the receipt of study 
vaccination through the 12-month  trial period.  
2. Known allergy or history of anaphylaxis, severe local or other serious adverse reactions to 
vaccines or vaccine products*, or history of severe allergic reactions.  
* This includes a known allergy to an aminoglycoside  (e.g., gentamicin, tobramycin, neomycin, 
streptomycin ).  
3. Received an experimental agent* within 3 months  prior to study vaccination, or expects to 
receive an experimental agent** during the 12 -month trial -reporting period.  
* Including vaccine, drug, biologic, dev ice, blood product, or medication.  
** Other than from participation in this study.  
DMID #[ADDRESS_1262863] 2019  
 
  
 
DMID/NIAID/NIH           36 
CONFIDENTIAL  
 4. Received any licensed live vaccine within 28 days prior to or after each study vaccination . 
5. Received a licensed inactivated vaccine within 14 days prior to or after each study 
vaccination .*  
* Allowable exception for inactivated seasonal influenza vaccine received more than 7 days prior to 
or after a study vaccination.  
6. Individuals in whom the ability to observe possible local reactions at the eligible injection 
sites (deltoid region) is, unacceptably obscured due to a physical condition or permanent 
body art.  
7. Have an acute illness*, as determined by [CONTACT_7880] [INVESTIGATOR_29353] -investigator, within 72 
hours prior to study vaccination.  
* An acute illness which is near ly resolved with only minor residual symptoms remaining is 
allowable if, in the opi[INVESTIGATOR_122740] -investigator, the residual symptoms 
will not interfere with the ability to assess safety parameters as required by [CONTACT_760]. Subje cts 
may re -screen after an acute illness is resolved  
8. Any confirmed or suspected immunosuppressive or immunodeficient condition * or use of 
anticancer chemotherapy or radiation therapy (cytotoxic) within 3 years prior to study 
vaccination.  
* including HIV in fection  
9. Administration of chronic (defined as more than 14 days) immunosuppressants or other 
immune modifying drugs within 6 months of receipt of study vaccine* 
*~ For corticosteroids, this means prednisone, or equivalent, greater than or equal to 0.5 mg/k g/day.   
Intranasal and topi[INVESTIGATOR_900578]; daily inhaled steroids for treatment of asthma NOT 
allowed.  
10. History of receipt of a Hantavirus vaccine, including vaccines for Hantaan  virus , Puumala  
virus , or combination of both.  
11. Exposed to A NDV* or plans to travel to an endemic area ^^ from enrollment through [ADDRESS_1262864] vaccination.  
*$ Residence in an ANDV endemic area in the last 3 years or >2 consecutive weeks of travel to an 
ANDV endemic area^^ in the last 3 years.  
**ANDV endemic areas include Chile, Brazil and Argentina6,[ADDRESS_1262865] within the 3 months before 
enrollment in this study.  
DMID #[ADDRESS_1262866] 2019  
 
  
 
DMID/NIAID/NIH           [ADDRESS_1262867] for this trial, or staff who 
are supervised by [CONTACT_978] [INVESTIGATOR_54720] -Investigators.  
21. Any condition that would, in the opi[INVESTIGATOR_900579] -
investigator, is a contraindication to study participation. * 
* Including acute or chronic (persisting for at least 90 days) clinically significant medical disease or 
condition, that would place the subject at an unacceptable risk of injury, render the subject unable 
to meet the requirements of the protocol, or may int erfere with the evaluation of responses or the 
subject’s successful completion of the study.  
5.3 Eligibility Criteria for Doses 2 -4 
Subjects may not receive subsequent vaccinations if any of the criteria in section 5.4.3  are met.  
Subsequent vaccinations may be deferred in subjects with transient acute illness as described in 
Section 5.4.3 .  
5.4 Treatment Assignment Procedures  
5.4.1 Enrollment and Randomization Procedures  
Per International Council for Harmonisation of Technical Requirements for Pharmaceuticals for 
Human Use (ICH) guideline E6: Good Clinical Practice (GCP), screening records  will be kept at 
the VTEU site to document the reason why an individual was screened, but failed trial entry 
criteria. The reasons why individuals failed screening will be recorded in the Statistical and Data 
Coordinating Center’s (SDCC) Advantage eClinica lSM (Electronic Data Capture System).  
 
DMID #[ADDRESS_1262868] 2019  
 
  
 
DMID/NIAID/NIH           [ADDRESS_1262869] -in-human Phase 1 study    
DMID #[ADDRESS_1262870] 2019  
 
  
 
DMID/NIAID/NIH           39 
CONFIDENTIAL  
 Table  1: Treatment Arm s. Sentinel subjects will be randomized 1:1 to dose regimen and will 
receive 2 mg o f study vaccine open label. The 22 non -sentinel subjects in Cohort s 1 and 2 will be 
randomized in a 9:2:9:2 ratio (Treatment Arms 1b:1c:2b:2c ) to receive either study vaccine or 
placebo at a dose of 2 mg in a 3 or 4 dose regimen, in double -blind fashion.   
 
The 24 participants in Cohorts 3  and 4 will follow the same schedule as outlined for Cohort s 1 
and 2 above. Sentinel subjects will receive 4 mg of study vaccine open label and be followed for 
safety through Day 8. The remaining 22 non -sentinel subjects in Cohort 3 and 4 will be 
randomized in a 9:2:9:2 (Treatment Arm s 3b:3c:4b:4 c) ratio to receive study vaccine or placebo 
at a dose of [ADDRESS_1262871].  
 
Instructions for use of the enrollment module are included in the Advantage eClinicalSM User’s 
Guide. Manual back -up randomization procedures and instructions  are provided for use in the 
event that the VTEU site temporarily loses access to the Internet or the online enrollment system 
is unavailable.  
 
Subjects who sign the informed consent form (ICF) and are randomized but do not receive study 
vaccine or placebo  may be replaced.  Subjects who sign the ICF, and are randomized and 
vaccinated, and subsequently withdraw, or are withdrawn or terminated from this trial, or are lost 
to follow -up will not be replaced.  
5.4.2 Masking Procedures  
Except for the sentinel subjects wh o will receive study vaccine open label, this is a double -blind 
clinical trial  within each dose escalation group (i.e., double blinded within Cohorts 1 and 2 and 
double blinded within Cohorts 3 and 4) . 
Investigators, study personnel performing any study -related assessments following study vaccine 
administration, and laboratory personnel performing antibody assays will be blinded to treatment 
arm assignment  (i.e., placebo vs. study vaccine, and dose regimen) . 
DMID #[ADDRESS_1262872] 2019  
 
  
 
DMID/NIAID/NIH           40 
CONFIDENTIAL  
 Sentinel subjects will be blinded to cohort , but not dosage group.  Non-sentinel subjects will be 
blinded to treatment arm assignment and cohort . 
The randomization scheme will be generated by [CONTACT_295016] (i.e., research pharmacists performing study vaccination preparations and unblinded 
study vaccine administrators) at the VTEU site.  
The unblinded study vaccine administrator is a study personnel member credentialed to 
administer vaccines and may also participate in dose preparation, but will not be i nvolved in 
study -related assessments or have subject contact [CONTACT_202406].  
 
The SMC may receive data in aggregate and presented by [CONTACT_2939]. The SMC may also be 
provided with expected and observed rates o f the expected AEs in an unblinded fashion, and may 
request the treatment arm be unblinded for an individual subject if required for safety 
assessment. The SMC will review grouped and unblinded data in the closed session only.  Refer 
to the protocol -specifi c Manual of Procedures (MOP) for unblinding procedures.  
5.4.[ADDRESS_1262873]’s study vaccine must be discontinu ed before the end of the 
vaccination schedule, this will not result in automatic withdrawal of the subject from the study.  
Subjects who discontinue study vaccine will be encouraged to remain in this trial for the 
following follow -up assessments:   
• Safety assessments: Venous blood sample at approximately [ADDRESS_1262874] study 
vaccination. Subjects will be asked to complete the remaining study assessments per 
Appendix A, Schedule of Events which may be conducted by [CONTACT_25600]/electronic 
communication ( e.g., email, text message) rather than in person continuing through 
approximately [ADDRESS_1262875] study vaccination.  
• Immunogenicity assessments: V enous blood sample at Day 29, [ADDRESS_1262876] study vaccination See the protocol -specific Manual of Procedures 
(MOP) for alternate follow -up requirements.  
Follow -up study vaccination s (2nd, 3rd and/or 4th dose) will not be administered to a subject if 
any of the following criteria are met : 
DMID #[ADDRESS_1262877] 2019  
 
  
 
DMID/NIAID/NIH           41 
CONFIDENTIAL  
 • Pregnancy  
• Receipt of disallowed licensed vaccine, experimental product or medication (see Section  5.2) 
• New onset of illness or condition that meets the Exclusion Criteria (see Section 5.2) 
• Medical condition or medication change for which continued participation, in the opi[INVESTIGATOR_900580] -investigator, wou ld pose a risk to the subject 
or would likely confound interpretation of the results.  Note: Medication changes subsequent 
to the first study vaccination are not exclusionary for receipt of the follow -up study 
vaccination provided there was no deterioration  in the subject’s chronic medical condition 
that necessitated a medication change, and there is no additional risk to the subject or 
interference with the evaluation of responses to study vaccination.  
• Presence of signs or symptoms that could confound or co nfuse assessment of study vaccine 
reactogenicity.   
• Any laryngospasm, bronchospasm, or anaphylaxis within [ADDRESS_1262878].  
• Any generalized urticaria after administration of study produ ct that is considered related to 
study product.  
• Serious adverse event related to the study vaccination.  
• Grade 3 solicited or unsolicited (clinical sign or symptom) adverse event that occurs in the [ADDRESS_1262879] has a Grade 3 adverse 
event as per Reactogenicity Tables 3, 4, 5 or 6 in the seven days following study vaccination 
and it lasts < 24 hours before dec reasing to a Grade 2 or Grade 1 adverse event, see 
discontinuation criteria for Grade 2 below.  
• Grade 3 solicited or unsolicited (clinical sign or symptom) adverse event that occurs >7 days 
following study vaccination and  is ongoing  at the time of the subs equent study vaccination 
(i.e., Day 29, Day 57 or Day 169).  Conversely, if this Grade 3 adverse event was resolved or 
reduced to a Grade 1 or Grade 2 adverse event at the time of the subsequent study 
vaccination , IP may only be given , following the documented determination by [CONTACT_360950] [INVESTIGATOR_29353] -investigator, that it would not render study 
vaccination unsafe or interfere with the evaluation of adverse events or immunologic 
response.  
• Grade 3 clinical safe ty laboratory value (according to the toxicity table, Section 9.2.2 ) that 
does not decrease to Grade 1 or less prior to the follow -up study vaccination  (i.e., Day 29, 
DMID #[ADDRESS_1262880] 2019  
 
  
 
DMID/NIAID/NIH           42 
CONFIDENTIAL  
 Day 57 or Day 169) . Any clinical safety laboratory parameter may be re -evaluated only once 
at the local  clinical laboratory to assess eligibility prior to the follow -up study vaccination . If 
the clinical safety laboratory value decreases to Grade [ADDRESS_1262881] may receive the 
follow -up study vaccination .  The study vaccination should be scheduled to occur within the 
acceptable protocol -specified window for that visit.  
• Subjects who experienced any Grade 2 adverse event that is an unresolved Grad e 2 or a 
Grade 1 at the time of the next vaccination, IP may only be given  following the documented 
determination by [CONTACT_16541] [INVESTIGATOR_29353] -investigator, that it would 
not render study vaccination unsafe or interfere with the ev aluation of adverse events or 
immunologic response.  
• As deemed necessary by [CONTACT_16541] [INVESTIGATOR_29353] -investigator for 
noncompliance or other reasons.  
• Subject refusal of further study vaccination.  
• Termination of this trial.  
• New info rmation becomes available that makes further administration of the study vaccine  
unsafe.  
Subjects with transient injection site or systemic signs or symptoms, or with an acute illness, 
including an oral temperature greater than or equal to 100.0°F, follow -up study vaccination/s 
should be postponed/deferred until signs, symptoms, or acute illness have resolved, or are 
improving as further specified below. Study vaccine given outside the protocol -specified window 
must be approved by [CONTACT_900617].   
• Note for afebrile, acute illness only:  If a subject is afebrile, his/her acute illness is nearly 
resolved with only minor residual symptoms remaining, this occurs within the acceptable 
protocol -specified window for that visit, and, in the opi[INVESTIGATOR_900581] -investigator, the residual symptoms will not interfere with the ability to 
assess safety parameters as required by [CONTACT_760], the subject may receive the follow -up 
study vaccination without DMID Medical Officer approval.   
5.4.[ADDRESS_1262882] may withdraw or  be withdrawn from this 
trial for any of the following reasons:  
DMID #[ADDRESS_1262883] 2019  
 
  
 
DMID/NIAID/NIH           43 
CONFIDENTIAL  
 • Medical disease or condition, or any new clinical finding for which continued participation, 
in the opi[INVESTIGATOR_29352] -investigator, would 
compromise  the safety of the subject, or would interfere with the subject's successful 
completion of this trial, or would interfere with the evaluation of adverse events or 
immunologic response.  
• As deemed necessary by [CONTACT_16541] [INVESTIGATOR_900582] s ub-investigator for 
noncompliance or other reasons.  
• Subject withdrawal of consent.  
• Subject lost to follow -up. 
• Subject dies.  
• Termination of this trial.  
• New information becomes available that makes further participation unsafe.  
5.4.[ADDRESS_1262884] to follow -up, extensive effort (i.e., three documented contact 
[CONTACT_92238], emails, text messages, etc., made on s eparate occasions and followed 
by a certified letter) will be made to locate or recall them, or at least to determine their health 
status. These efforts will be documented in the subject’s study records. Every attempt will be 
made to follow all adverse eve nts, including solicited local site and systemic AEs, unsolicited 
non-serious adverse events and SAEs, ongoing at the time of early withdrawal through resolution 
as per applicable collection times defined for the specific type of adverse event.  
Subjects wh o withdraw, or are withdrawn or terminated from this trial, or are lost to follow -up 
after signing the ICF, randomization, and receipt of study vaccine will not be replaced. Subjects 
who withdraw, or are withdrawn or terminated from this trial, or are lost  to follow -up after 
signing the ICF and randomization but before receipt of study vaccine may be replaced.  
5.4.6 Termination of Study  
Although the sponsor has every intention of completing this trial, it reserves the right to 
terminate this trial at any time for  clinical or administrative reasons. Reasons for termination 
DMID #[ADDRESS_1262885] 2019  
 
  
 
DMID/NIAID/NIH           44 
CONFIDENTIAL  
 include, but are not limited to, study closure due to the recommendation after a SMC review and 
at the discretion of DMID.  
DMID #[ADDRESS_1262886] 2019  
 
  
 
DMID/NIAID/NIH           45 
CONFIDENTIAL  
 6 STUDY INTERVENTION/INVESTIGATIONAL PRODUCT  
6.[ADDRESS_1262887] Description  
AND V DNA vaccine is a deoxyribonucleic acid (DNA) vaccine . The ANDV DNA vaccine 
plasmid is constructed on a well -characterized plasmid backbone, pWRG7077, and elements of 
the ANDV genome. The plasmid used for the ANDV DNA vaccine, pWRG/AND -M (opt2), is 
optimized for homo sapi[INVESTIGATOR_900583] . The vaccine was 
developed by [CONTACT_900608], US Army Medical Research Institute of 
Infectious Diseases ([LOCATION_003]MRIID; Fort Detrick, Maryland), and the final vaccine was 
manufactured by [CONTACT_900598] (Fargo, ND).  
The ANDV DNA vaccine drug substance, plasmid pWRG/AND - M(opt2), Lot # [ZIP_CODE] , date of 
manufacture 0 1 Dec 2017, was diluted to a concentration of 4.0 +/ - 0.2 mg/mL in phosphate -
buffered saline ( PBS) at a pH of 7.2, ster ile-filtered, and stored as bulk after aliquots were 
removed for stability, sterility, and quality control ( QC) testing.  
The ANDV DNA plasmid that forms the active component for the vaccine is suspended in PBS. 
Each injection will contain  1 or 2 mg of DNA in 0.5 mL of PBS  depending on randomization 
assignment ; it is c lear, colorless and  free of visible particulate . 
6.1.1 Acquisition  
The ANDV DNA vaccine will be provided by [CONTACT_900598] (Fargo, ND) . Placebo  and Diluent , 0.9% 
Sodium Chloride Injection, USP will be prov ided by [CONTACT_319655]  
(CMS), Fisher BioServices,  and will be shipped to the investigational site upon request and 
approval by [CONTACT_122830].  
Upon request by [CONTACT_122830], ANDV  DNA Vaccine will be shipped  to the following address:  
DMID Clinical Materials Services   
Fisher BioServices  
[ADDRESS_1262888]  
Germantown, MD [ZIP_CODE]  
 
ANDV  DNA vaccine , placebo  and diluent  will be provided through the DMID Clinical Materials 
Services  (CMS ) to the VTEU site prior to the start of this trial upon request and with prior 
approval from DMID. Should the site principal investigator [INVESTIGATOR_900584], further instructions are provided in the protocol -specific MOP.  
DMID #[ADDRESS_1262889] 2019  
 
  
 
DMID/NIAID/NIH           46 
CONFIDENTIAL  
 6.1.2 Formulation, Packaging, and Labeling  
ANDV DNA Vaccine  
The ANDV DNA vaccine comes in single -use vials. Vials for the Phase 1 clinical trial will be 
fill-finished at 1. 3 mL per vial. This will allow two 0.5 mL PharmaJet Stratis® Needle -Free 
Injection System syringes to be filled from each vial.   
 
The vaccine formulates will be administered  using the PharmaJet Stratis® Needle -Free Injection 
System . This device delivers a 0.[ADDRESS_1262890] will be labeled according to manufacturer specifications and include the 
statement “Caution: New Drug – Limited by [CONTACT_12201]” . 
Placebo /Diluent  
 
Placebo and diluent will be supplied as 0 .9% Sodium Chloride Injection, USP which is a sterile, 
nonpyrogenic, isotonic solution of sodium chloride and water for injection (WFI). Each mL 
contains sodium chloride 9 mg  without any preservative . It contains no  bacteriostatic, 
antimicrobial agent, or added buffer and is supplied only in single -dose containers.  The solution 
may contain hydrochloric acid and/or sodium hydroxide for pH adjustment (pH 5.3 [4.5 to 7.0]).  
The placebo will be administered  using the PharmaJet Stratis® Needle -Free Injection System . 
This device delivers a 0.[ADDRESS_1262891] be stored at ≤ - 65º C. Vials are removed from the 
product freezer and thawed at room temperature for at least 30 minutes  and administered within 
1 hour after thawing .  
 
 
DMID #[ADDRESS_1262892] 2019  
 
  
 
DMID/NIAID/NIH           47 
CONFIDENTIAL  
 Placebo /Diluent  
Placebo and diluent must be stored at 20ºC to 25ºC (68°F to 77ºF) [See USP Controlled Room 
Temperature; excursions between 15°C and 30°C (59°F and 86°F) are permitted]. See protocol -
specific MOP for further instructions.  
The temperature of the storage unit must be recorded daily (excluding non -business days and 
holidays as applicable), continuousl y monitored and recorded during the duration of this trial per 
the VTEU site’ s standard operating procedures  (SOP) , and documentation will be maintained. If 
the temperature fluctuates outside of the required range, the affected study product(s) must be 
quarantined at the correct storage temperature and labeled as ‘Do Not Use’ (until further notice). 
The research pharmacist must alert the site principal investigator [INVESTIGATOR_32528], if the 
temperature fluctuates outside of the required range. In the ev ent the temperature fluctuates 
outside of the required range, the affected study product(s) must not be administered. The site 
principal investigator [INVESTIGATOR_900585] t the DMID Product 
Support Team  (see MOP for contact [CONTACT_71126]) for further instructions before any additional 
study vaccinations are administered. Based on the information collected, DMID and/or the 
manufacturer will determine whether the affected study product(s) can be used. If it cannot be 
used, the site wil l receive specific instructions on how to return the affected study product(s) to 
the DMID CMS or destroy it on site. Additional instructions for quarantine are provided in the 
protocol -specific MOP.  
6.2 Dosage, Preparation and Administration of Study 
Interven tion/Investigational Product  
See the protocol -specific MOP for detailed information on the preparation, labeling, storage, and 
administration of study product for each cohort . Study product preparation will be performed by 
[CONTACT_900618]’ s research pharmaci st on the same day of study vaccine administration.  
 
Visually inspect the ANDV  DNA vaccine  upon receipt and prior to use. If the study product(s) 
appear(s) to have been damaged, contaminated or discolored, contain visible particulate matter or 
if there are any concerns regarding its integrity, do NOT use the affected study product(s). The 
affec ted study product(s) must be quarantined at ≤ - 65 ºC  and labeled as ‘Do Not Use’ (until 
further notice). The site principal investigator [INVESTIGATOR_900586] (see MOP for contact [CONTACT_3031])  and D MID Clinical Project 
Manager for further instructions before any additional study vaccinations are administered. 
Based on the information collected, DMID and/or the manufacturer will determine whether the 
DMID #[ADDRESS_1262893] 2019  
 
  
 
DMID/NIAID/NIH           [ADDRESS_1262894](s) can be used. If it cannot  be used, the site will receive specific 
instructions on how to return the affected study product(s) to the DMID CMS or destroy it on 
site. If the ANDV  vaccine is unusable, study personnel will use another vial from the study 
supply. Replacement vials may be requested by [CONTACT_295023]. Additional instructions for 
quarantine and DMID contact [CONTACT_295025] -specific MOP.  
 
The st udy product will be prepared for administration by  [CONTACT_900619] [ADDRESS_1262895] a clear appear ance after thawing .  
 
Dilution is not required for subjects allocated to the 4  mg dosage cohorts, the dose will be 
divided into 2 mg per 0.5 mL administration into the left and right deltoid muscles. Dilution with 
0.9% Sodium Chloride Injection, USP is req uired for subjects allocated to the [ADDRESS_1262896] s will be a total of 1.0 ml; 0.5 ml of  ANDV  
DNA  vaccine (diluted to 1 .0 mg/0 .5 mL) administered in to both the left and right  deltoid  
muscles.     
 
The volume  administered to Cohort 3 and 4  subjects will be a total of 1.0 ml; 0.5 ml ANDV  
DNA  vaccine (2.0 mg/0.5 ml) administered into both  the left and right deltoid  muscle s.  
 
Study product administration will be performed by [CONTACT_900620], but will not be 
involved in study -related assessments or have subject contact [CONTACT_900621].  
6.3 Modification of Study Intervention/Investigational Product for a 
Participant  
Subjects who do not receive  follow -up vaccinations (2, 3 or 4 ) within the protocol defined 
window  will be followed for safety and immunogenicity . 
Outside of protocol defined windows,  there will be no dose modifications . 
DMID #[ADDRESS_1262897] 2019  
 
  
 
DMID/NIAID/NIH           [ADDRESS_1262898]’s follow -up vaccinations are deferred, attempts wi ll be made to reschedul e the 
vaccination  to occur within the acceptable protocol -specified window for that visit.   
Subjects who do not receive the follow -up study vaccination will continue with follow -up safety 
and immunogenicity  assessments continuing through approximately [ADDRESS_1262899] 
study vaccination. See Sections 5.4.3 , 5.4.4  and 5.4.5  for reasons for and handling of 
withdrawals and discontinuation of treatment. See the protocol -specific MOP for alternate 
follow -up requirements.    
6.4 Accountability Procedures for the Study Intervention/Investigational 
Product(s)  
After receipt of the ANDV vaccine, the site principal investigator [INVESTIGATOR_900587].    As this is a blinded study, the site PI [INVESTIGATOR_900588]. Study vaccine records must be maintained and document logs of 
receipt, accountability, and storage temperature conditions. The study product accountability 
records and dispensing logs will also capture vial numbers, including fi nal vial number, date of 
study vaccine preparation/ administration, time of study vaccine preparation, time study vaccine 
is drawn into the syringe, and amount of study vaccine withdrawn for administration. Time of 
study vaccine administration to the subje ct will be captured on the appropriate data collection 
form. All study product(s), whether administered or not, must be documented on the appropriate 
study product accountability record or dispensing log. The sponsor's monitoring staff will verify 
the VTEU  site’s study product accountability records and dispensing logs per the site monitoring 
plan.  
Used and unused vials of vaccine, will be retained until monitored and released for disposition as 
applicable. The injectors are re -usable , syringes are disposab le. Used syringes  post dosing may 
be disposed of upon completion of administration. Filled, un -used syringes  will be retained until 
monitored and released for disposition as applicable. Final disposition of the unused vaccine will 
be determined by [CONTACT_900622] e enrolling  site. 
DMID #[ADDRESS_1262900] 2019  
 
  
 
DMID/NIAID/NIH           [ADDRESS_1262901] Compliance with Study 
Intervention/Investigational Product  
Study products will be administered to subjects via intramuscular injection  according to subject 
treatment assignment and as described in Section 6.2. Thus , subject compliance is not anticipated 
to be an issue. Deviations from the dose sch edule may only occur as described in Section 6.3. 
6.6 Concomitant Medications/Treatments  
Administration of any medications, therapi[INVESTIGATOR_014], or non-study vaccines will be rec orded on the 
appropriate data collection form. Concomitant medications will include all current medications 
and medications taken within [ADDRESS_1262902] study vaccination or early termination (i f prior to [ADDRESS_1262903] study 
vaccination), whichever occurs first. Medications will include prescription and over -the-counter 
drugs as well as herbals, vitamins, and supplements. Medications and non -study vaccines 
reported in the electronic case  report form (eCRF) are limited to those received  within [ADDRESS_1262904](s) should not 
be used from time of study vaccination through [ADDRESS_1262905]’s health care. Medications  in this category include the prohibited 
medications per the Subject Exclusion Criteria (see Section 5.2). In addition, the  site principal 
investigator [INVESTIGATOR_900589] -investigator may identify other medications that should not be 
used due to a risk to subject safety or assessment of reactogenicity and immunogenicity.  Use of 
medications (anti-inflammatories or analgesics) as prophylaxis prior to study vaccination is 
prohibited.  There are no known drug -vaccine interactions with the study vaccine and subjects are 
not being asked to discontinue current medications not listed in the exclusion criteria.  
In the event medical conditions dictate use of medicat ions, subjects are encouraged to obtain 
adequate care, comply with the course of therapy as prescribed by [CONTACT_900623]. Details of all medications taken during the medication reporting 
period for this study (da te, indication , brand or generic name) will be recorded.  Use of new 
medication should prompt evaluation for the occurrence of an AE or worsening of a pre -existing 
medical condition.  
 
DMID #[ADDRESS_1262906] 2019  
 
  
 
DMID/NIAID/NIH           51 
CONFIDENTIAL  
 7 STUDY SCHEDULE  
Complete study schedule details listed by [CONTACT_900624] e described below. Refer also to 
Sections 4 and 8, and Appendix A: Schedule of Events . 
7.1 Screening  
Day -28 to -1, Visit 00  
Potential subjects will be screened for eligibility within 28 days prior to the administration of 
study vaccination. The following activities will be performed  at screening  and may be done all at 
one visit or split into separate visits  for all Treatment Ar ms: 
• Subjects will be provided with a description of this trial (purpose and study procedures) and 
asked to read and sign the ICF. The ICF will be signed prior to performing any study 
procedures, including any screening procedures.  
• Demographic information w ill be obtained by [CONTACT_202415].  
• Eligibility criteria will be reviewed with subjects.  The following screening procedures will be 
completed  to ensure that the potential subject is eligible for the study:  
• Complete medical history will be obtained by  [CONTACT_202415].  
• History of a ll concomitant medications taken within [ADDRESS_1262907] Inclusion and Exclusion Criteria (see 
Section 5.1, 5.2, 5.3).  
• Vital signs, including oral temperature, pulse, and blood pressure, will be obtained. Subjects 
must not eat or drink anything hot or cold, or smoke within 10 minutes prior to taking oral 
temperature.  
• Height and weight will be collected . 
• A physical examination will be performed to include the following organs and organ 
systems: general appearance, skin, head and neck, lungs, heart, liver, spleen, extremities, 
musculoskeletal, lymph nodes, and nervous system by a study clinician licensed to make 
medical diagnoses and listed on the Form FDA 1572 as the site principal  investigator [INVESTIGATOR_11637] -
investigator.  
DMID #[ADDRESS_1262908] 2019  
 
  
 
DMID/NIAID/NIH           52 
CONFIDENTIAL  
 • A serum pregnancy test will be performed on all females of childbearing potential and must 
be negative.  
• Venous blood will be collected for screening laboratory tests to be run at the local clinical 
laboratory. These inclu de: WBC , Hgb, platelet  count , ANC, sodium, potassium, and 
creatinine , HgbA1C, total bilirubin , and ALT.  BUN will be obtained if creatinine is above 
the normal range. In addition , participants will be screened for HIV  – 1/[ADDRESS_1262909] be confirmed to meet the eligibility criteria as 
outlined in the Inclusion Criteria (see Section 5.1 and Appendix B) prior to randomization.    
• Urine will be collected for screening  urinalysis (dipstick) for urine protein  and u rine 
toxicology  screen for opi[INVESTIGATOR_858]. Values must meet the eligibility criteria (see Section 5) prior to 
randomi zation.  
7.2 Enrollment/Baseline   
Day 1, Visit [ADDRESS_1262910].  The following procedures will occur for all Treatment Arms:  
• Subject’s willingness to participate will be reconfirmed prior to performing any further study 
procedu res, including administration of the study vaccination.  
• Eligibility criteria, including results of all clinical screening laboratory evaluations, will be 
reviewed with subjects prior to study vaccination to ensure continued eligibility.  
• Complete medical hi story and any updates obtained by [CONTACT_900625].  
• All concomitant medications will be reviewed with subjects prior to study vaccinati on for 
accuracy and completeness. Any new concomitant medications taken since the screening 
visit will be reviewed with subjects and assessed for continued eligibility prior to study 
vaccination. Medications reported in the eCRF are limited to those taken within 30 days prior 
to study vaccination.  
• Vital signs, including oral temperature, pulse, and blood pressure, will be obtained to ensure 
eligibility. Vital signs assessed on Day [ADDRESS_1262911] not eat or drink anything hot or cold, or smoke within 
10 minutes prior to taking oral temperature.  
DMID #[ADDRESS_1262912] 2019  
 
  
 
DMID/NIAID/NIH           53 
CONFIDENTIAL  
 • A targeted physical examination may be performed prior to study vaccination, if indicated 
based on review of complete medical history and any update s obtained by [CONTACT_319670], by a study clinician listed on the Form FDA 1572.  
• A urine pregnancy test will be performed within [ADDRESS_1262913] be n egative and known prior to 
randomization and study vaccination.  
• Subjects will be enrolled in Advantage eClinical SM and assigned randomly to a treatment 
arm prior to study vaccination.  
• Venous blood will be collected immediately prior to the study vaccinatio n for baseline 
ANDV PRNT and PsVNA antibody assays.  
• Venous blood will be collected immediately prior to the study vaccination for  baseline  safety 
labs.  
• Venous blood will be collected immediately prior to the study vaccination for baseline ICS 
and LPA cellular assays.  
• Pre-administration systemic  reactogenicity assessments will be performed prior to study 
vaccination to establish a baseline. Subjects will t hen receive study vaccin ation via 
intramuscular injection  into the left and right deltoid  one after another  or simultaneously . The 
time of administration will be recorded on the appropriate data collection form. Subjects will 
be observed for at least [ADDRESS_1262914] -
administration local and systemic  reactogenicity  assessments will be performed.  Any 
AE/SAEs will be recorded on the appropriate data collection form prior to discharge from the 
clinic.   
• Subjects will be provided with a memory aid and other study -related materials to record daily 
oral temperature, solicited site and systemic AEs, unsolicited AEs, and concomitant 
medications. Subjects will be encouraged to take their oral temperature around the same time  
each day. Subjects must not eat or drink anything hot or cold, or smoke within [ADDRESS_1262915] on the proper course 
of action, including a return to the clinic for immediate evaluation if appropriate.  
DMID #[ADDRESS_1262916] 2019  
 
  
 
DMID/NIAID/NIH           54 
CONFIDENTIAL  
 7.3 Follow -up, Vaccination Visits   
Day 29  (+2), 57 (+2), 169 (+5)  
Follow -up visits are scheduled in reference to study vaccination date as indi cated for each visit 
window , see Appendix A, SOE . All Treatment Arms will return for vaccination on D29 (V3) , 
D57 (V5)  and D169 (V 9).   
• Eligibility criteria will be reviewed with subjects prior to study vaccination to ensure 
continued eligibility.  
• Interim medical history will be obtained by [CONTACT_900626]. Any changes since the previous clinic visit or contact 
[CONTACT_319668].  
• All concomitant medication s (including solicitation for receipt of any non -study vaccines) 
will be recorded on the appropriate data collection form at each clinic visit. Any new 
concomitant medications taken since the screening visit will be reviewed with subjects and 
assessed for continued eligibility prior to study vaccination.  
• Vital signs, including oral temperature, pulse, and blood pressure, will be obtained to ensure 
eligibility. Subjects must not eat or drink anything hot or cold, or smoke within 10 minutes 
prior to taking or al temperature.  
• A targeted physical examination may be performed prior to study vaccination, if indicated 
based on review of complete medical history and any updates obtained by [CONTACT_900627], by a study clinician listed on the Form FDA 1572.  
• A uri ne pregnancy test will be performed within [ADDRESS_1262917] be negative and known prior to 
administration of study vaccination.  
• Venous blood will be collected immediately prior to th e study vaccination (D29) for ANDV 
PsVNA antibody assays.  
• Venous blood will be collected at Days 57 and 169 immediately prior to the study 
vaccination for ANDV PsVNA and PRNT antibody assays.  
• Venous blood will be collected immediately prior to the study vaccination for safety labs  on 
Day 169 only .  
• Venous blood will be collected immediately prior to the study vaccination for ICS and LPA 
cellular assays.  
DMID #[ADDRESS_1262918] 2019  
 
  
 
DMID/NIAID/NIH           55 
CONFIDENTIAL  
 • Pre-administration  systemic  reactogenicity assessments will be performed prior to study 
vaccinati on to establish a baseline. Subjects will then receive the dose of study vaccine via 
intramuscular injection into the left and right deltoid  one after another  or simultaneously . The 
time of administration will be recorded on the appropriate data collection  form. Subjects will 
be observed for at least [ADDRESS_1262919] -
administration  local and systemic  reactogenicity assessments will be performed. Any 
AE/SAEs will be recorded on the appropriate data collection form p rior to discharge from the 
clinic.   
• Subjects will be provided with a memory aid and other study -related materials to record daily 
oral temperature, solicited site and systemic AEs, unsolicited AEs, and concomitant 
medications. Subjects will be encouraged to take their oral temperature around the same time 
each day. Subjects must not eat or drink anything hot or cold, or smoke within [ADDRESS_1262920] on the proper course 
of action, including a return to the clinic for immediate evaluation if appropriate.  
• All AEs and SAEs will be collected and recorded on the appropriate data collection form a t 
each clinic visit.  
7.[ADDRESS_1262921] each vaccination  
Day 8  (+2), 36 (+2), 64 (+2), 176 (+2)  
Follow -up visits are scheduled in reference to study vaccination date as indicated for each visit 
window , see Appendix A, SOE . All Treatment Arms will return on D8 (V2), D36 (V4), D64  
(V6) and D1 76 (V10). 
• Interim medical history will be obtained by [CONTACT_319664]. Any changes since the previous clinic visit or contact [CONTACT_900628].  
• All concomitant medications (including solicitation for receipt of any non -study vaccines) 
will be recorded on the appropriate data collection form at each clinic visit. Any new 
concomitant medications taken since the last clinic visit or phone con tact will be reviewed 
with subjects and assessed for continued eligibility.  
DMID #[ADDRESS_1262922] 2019  
 
  
 
DMID/NIAID/NIH           56 
CONFIDENTIAL  
 • A targeted physical examination may be performed, if indicated based on review of complete 
medical history and any updates obtained by [CONTACT_202415], by a study clinician l isted 
on the Form FDA.  
• Venous blood will be collected for safety labs.  
• All AEs  and SAEs will be collected and recorded on the appropriate data collection form at 
each clinic visit.  
• Memory aid information will be reviewed with subjects at each clinic  visit. 
7.[ADDRESS_1262923] vaccination on D85  
(V7) and D1 97 (V11 ). 
• Interim medical history will be obtained by [CONTACT_319664]. Any changes since the previous clinic visit or contact [CONTACT_319665].  
• All concomitant medications (including solicitation for receipt of any non -study vaccines) 
will be recorded on the appropriate data collection form at Day [ADDRESS_1262924] will be reviewed 
with subjects and assessed for continued eligibility.  
• A targeted physical examination may be performed, if indicated based on review of complete 
medical history and any updates obtained by [CONTACT_202415], by a study clinician listed 
on the Form FDA 1572.  
• Venous blood will be coll ected for ANDV PRNT  and PsVNA  antibody assays.  
• Venous b lood will be collected  for future exploratory assays  
• Venous blood will be collected for ICS and LPA cellular assays.  
• All AEs  and SAEs will be collected and recorded on the appropriate data collection f orm at 
each clinic visit.  
 
DMID #[ADDRESS_1262925] 2019  
 
  
 
DMID/NIAID/NIH           57 
CONFIDENTIAL  
 7.6 Follow -up Visits  
Day 141 & 253  
Follow -up visits are scheduled in reference to study vaccination date as indicated for each visit 
window , see Appendix A, SOE . All Treatment Arms will return on D141  (V8) and D 253 (V12 ). 
• Interim medical history will be obtained by [CONTACT_319664]. Any changes since the previous clinic visit or contact [CONTACT_319665].  
• All concomitant medications (including solicitation for receipt of  any non -study vaccines) 
will be recorded on the appropriate data collection form at the Day [ADDRESS_1262926] will be reviewed 
with subjects and assessed for continued eligib ility. 
• A targeted physical examination may be performed, if indicated based on review of complete 
medical history and any updates obtained by [CONTACT_202415], by a study clinician listed 
on the Form FDA 1572.  
• Venous blood will be collected for ANDV PsVNA  antibody assays  at Day 253 . 
• All AEs  will be collected and recorded on the appropriate data collection form at day 141.   
• SAEs will be collected and recorded on the appropriate data collection form at each clinic 
visit.  
7.7 Final Study Visit   
Day 337  
Final visits are scheduled in reference to study vaccination date as indicated for each visit 
window , see Appendix A, SOE . All treatment Arms will return on D337 (V13) . 
• Interim medical history will be obta ined by [CONTACT_202415]. Any changes since th e 
previous clinic visit or contact [CONTACT_319673].  
• A targeted physical examination may be performed, if indicated based on review of complete 
medical history and any updates obtained by [CONTACT_202415], by a study clinician listed 
on the Form FDA 1572 . 
• Venous blood will be collected for future exploratory assays .  
• Venous blood will be collected for ANDV PsVNA  antibody assays.  
DMID #[ADDRESS_1262927] 2019  
 
  
 
DMID/NIAID/NIH           58 
CONFIDENTIAL  
 • All SAEs will be collected and recorded on the appropriate data collection form.  
7.8 Early Termination Visit  
The following activiti es will be performed on all Treatment Arms at the early termination visit 
on subjects who withdraw, or are withdrawn or terminated from this trial:  
• Interim medical history will be obtained by [CONTACT_319674] (if indicated).  
• Memory aid information will be reviewed with subjects (if within [ADDRESS_1262928] study 
vaccination).  
• All concomitant medications (including solicitation for receipt of any non -study vaccines) 
will be recorded on the appropriate data collection form (if prior to [ADDRESS_1262929] study 
vaccination).  
• All AE/SAEs will be recorded on the appropriate data collection form. AEs will be recorded 
if prior to [ADDRESS_1262930] study vaccination.  
• Vital signs, including oral temperature, pulse, and blood pressure, may be obtained if 
indicated. Subjects must not eat or drink anything hot or cold, or smoke within 10 minutes 
prior to taking ora l temperature.  
• A targeted physical examination may be performed, if indicated based on review of interim 
medical history, by a study clinician licensed listed on the Form FDA 1572.  
• Post-administration reactogenicity assessments will be performed (if within  [ADDRESS_1262931] study 
vaccination).  
• Venous blood will be collected for safety laboratory evaluations and performed by [CONTACT_126259] 
(clinical) laboratory (if within [ADDRESS_1262932] study vaccination).  
• Venous blood will be collected for cellular (ICS, LPA) assays  (if prior to [ADDRESS_1262933] 
study vaccination).  
• Venous blood will be collected for PsVNA antibody assays.  
7.9 Unscheduled Visit  
Unscheduled visits may occur at any time during this trial.  Any of th e following activities may 
be performed:  
DMID #[ADDRESS_1262934] 2019  
 
  
 
DMID/NIAID/NIH           59 
CONFIDENTIAL  
 • Interim medical h istory will be obtained by [CONTACT_319674] (if indicated).  
• Memory aid information will be reviewed with subjects (if within [ADDRESS_1262935] study 
vaccination).  
• All concomitant medic ations (including solicitation for receipt of any non -study vaccines) 
will be recorded on the appropriate data collection form (if prior to [ADDRESS_1262936] study 
vaccination).  
• All AE/SAEs will be recorded on the appropriate data collection form. AEs will  be recorded 
if prior to [ADDRESS_1262937] study vaccination.  
• Vital signs, including oral temperature, pulse, and blood pressure, may be obtained if 
indicated. Subjects must not eat  or drink anything hot or cold, or smoke within 10 minutes 
prior to taking oral temperature.  
• A targeted physical examination may be performed, if indicated based on review of interim 
medical history, by a study clinician listed on the Form FDA 1572.  
• Post-administration reactogenicity assessments will be performed (if within [ADDRESS_1262938] study 
vaccination).  
• Venous blood will be collected for safety laboratory evaluations and performed by [CONTACT_126259] 
(clinical) laboratory (if within [ADDRESS_1262939] study vaccin ation).  
• Venous blood will be collected for cellular (ICS, LPA) assays (if prior to [ADDRESS_1262940] 
study vaccination).  
• Venous blood will be collected for PsVNA antibody assays.  
 
DMID #[ADDRESS_1262941] 2019  
 
  
 
DMID/NIAID/NIH           60 
CONFIDENTIAL  
 8 STUDY PROCEDURES/EVALUATIONS  
8.1 Clinical Evaluations  
Complete medical history w ill be obtained by [CONTACT_319676]/or updated on Day [ADDRESS_1262942], liver, pancreas, kidney, urologic system, 
nervous system, blood, lymph nodes, endocrine system, musculoskeletal system, skin, and 
genital/reproductive tract. A history of any allergies, cancer, imm unodeficiency, psychiatric 
illness, substance abuse, and autoimmune disease will be solicited. At follow -up visits after study 
vaccination, an interim medical history will be obtained by [CONTACT_900629]. The interim medical history should include an 
assessment for new medical conditions.  
 
Medication history (concomitant medications) will include a review of all current medications 
and medications taken within [ADDRESS_1262943] study vaccination or early termination (if prior to [ADDRESS_1262944] study 
vaccination), whichever occurs first. Medications reported in the eCRF are limited to those taken 
within [ADDRESS_1262945] Inclusion and Exclusion Criteria (see Sections 5.1 and 5.2). In 
addit ion, the site principal investigator [INVESTIGATOR_29353] -investigator may identify other 
medications that should not be used due to a risk to subject safety or assessment of reactogenicity 
and immunogenicity.  History of non -study vaccines received from [ADDRESS_1262946] study vaccination will be solicited and 
recorded on the  eCRF.  
 
A full physical examination will be performed on all subjects at the screening visit. This exam 
will include the following organs and organ systems: general appearance, skin, head and neck, 
lungs, heart, liver, spleen, extremities, musculoskeletal,  lymph nodes and nervous system, by a 
study clinician licensed to make medical diagnoses and listed on the Form FDA 1572 as the site 
principal investigator [INVESTIGATOR_11637] -investigator.   
 
DMID #[ADDRESS_1262947] 2019  
 
  
 
DMID/NIAID/NIH           61 
CONFIDENTIAL  
 Vital signs (oral temperature, pulse, and blood pressure) will be collected a t the screening visit. 
Subjects must not eat or drink anything hot or cold, or smoke within [ADDRESS_1262948]’s interim 
medical history, by a study clinician licensed to make medical diagnoses and listed on the Form 
FDA 1572 as the site principal investigator [INVESTIGATOR_11637] -investigator.  
 
On Day 1 and all vaccination visits, vital signs (oral temperature, pulse, and blood pressure) will 
be collected prior to study vaccination. A urine pregnancy test will be performed within [ADDRESS_1262949] -
administration reactogenicity assessments will be performed and any AE/SAEs will be recorded 
on the appropriate data collection form prior to discharge from the clinic. All subjects will 
receive and complete a subject memory aid from the time of study vaccination through [ADDRESS_1262950] memory aids will be reviewed with the subjects for adverse 
events, (solicited  local and systemic AEs and unsolicited AEs) approximately 7 days  after each 
vaccination.  
 
Reactogenicity assessments will include an assessment of solicited adverse events occurring 
from the time of study vaccination through 7 days after study vaccination . These include local 
reactions such as pain, tenderness, erythema (redness), induration (hardness/swelling), bruising  
and skin discoloration  as well as sy stemic AEs such as fever, feverishness (chills, shivering, 
sweating), fatigue (tiredness), malaise (general unwell feeling), myalgia (body aches/muscular 
pain), nausea, dizziness and headache.  
8.[ADDRESS_1262951] will be performed within 24 hours 
prior to study vaccination on all females of childbearing potential. Urine will be collected in a 
DMID #[ADDRESS_1262952] 2019  
 
  
 
DMID/NIAID/NIH           [ADDRESS_1262953] be negative and known prior to randomization on Day 1 and prior to administration 
of study vaccination on Day 29, Day 57 and Day 169 . 
 
Clinical screening laboratory  tests will be performed at the screeni ng visit and processed by [CONTACT_213691] (clinical) laboratory . Parameters to be evaluated to confirm trial eligibility as per Section 
5.1 and Appendix B, include  the following : 
• Hematology : WBC , Hgb, platelet  count , ANC , and HgbA1c.   
• Biochemistry: Total bilirubin, ALT, creatinine , sodium , and potassium.  BUN will be done if 
creatinine is above the normal range.    
• Serum serology testing for HIV – 1/2 antibody , HCV antibody, and HBsAg.  
• Serum βHCG pregnancy test (all females  of childbearing potential ) at screening  and urine 
pregnancy test as described above .   
• Urinalysis will be done to test for urine protein via dipstick in the clinic.  Clean -catch, mid -
stream, urine specimen will be collected in a sterile urine cup.  
• Urine t est for opi[INVESTIGATOR_858]: A clean -catch, mid -stream urine specimen will be collected in a ster ile 
urine cup and transported to the clinical laboratory for processing and examination.  
 
Clinical s afety labs will be performed at Day 1  and 169, and approximately 7 days after each 
study vaccination . If they are abnormal,  tests will be  repeated at the next scheduled visit (or 
sooner if medically indicated) and followed to normal or stabilization.  Clinical safety laboratory 
parameters to be evaluated will include WBC , Hgb, platelet  count , ANC , sodium, potassium, 
Creatinine, total bilirubin and ALT. These evaluations will be performed by [CONTACT_126259] (clinical) 
laboratory  and will not be used for screening purposes prior to dosing.  
 
The volume of venous blood to be collected for clinical screening , immunologic assessments  and 
safety laboratory evaluations is presented in the table s below : 
 
  
DMID #[ADDRESS_1262954] 2019  
 
  
 
DMID/NIAID/NIH           63 
CONFIDENTIAL  
 Table 2: Blood Volume (mL) – All Treatment Arms  
Study  Visit (V)  00 01 02 03 04 05 06 07 08 09 10 11 12 13 U/S 
or ET  
Study Day and 
Window  Screen  D1 D8 D29 D36 D57 D64 D85 D141  D169  D176  D197  D253  D337   
Screening Labs  20               
Clinical Safety 
Evaluations   6.5 6.5  6.5  6.5   6.5 6.5    6.5 
PBMCs (ICS, 
LPA)   40  40  40  40  40  40   40 
Immunogenicity 
(ANDV PRNT)   10    10  10  10  10    
Immunogenicity 
(ANDV PsVNA)   10  10  10  10  10  10 10 10 10 
Future Exploratory 
Assays         40    40  40  
Total volume of 
blood 
collected/visit  20 66.5 6.5 50 6.5 60 6.5 100 0 66.5 6.5 100 10 50 56.5 
Cumulative 
volume of blood  20 86.5 93 143 149.
5 209.5  216 316 316 382.5  389 489 499 549 N/A 
8.2.2 Acceptable Laboratory Values for Eligibility and Defining Normal V alues 
If laboratory screening tests are out of acceptable range, repeat of screening tests is permitted once, 
provided there is an alternative explanation for the out of range value.   
Refer to Appendix B for acceptable values for study eligibility and  clinical laboratory reference 
ranges.  
• Absolut e neutrophil counts  (ANC)  below the laboratory normal reference range will be 
allowable if they are in keepi[INVESTIGATOR_900590] a condition that is prevalent in our 
population known as “benign ethnic neutropenia.”  For subjects who are of African Ame rican 
or Middle Eastern decent, ANC must be greater than or equal to 0.8 K/mcL  for inclusion.  
• Creatinine, BUN,  and ALT values that are below the lower limit of normal as presented in 
Appendix B are not exclusionary as these values are considered to be not clinically  
significant  (NCS) .  
DMID #[ADDRESS_1262955] 2019  
 
  
 
DMID/NIAID/NIH           64 
CONFIDENTIAL  
 • If a creatinine level is abnormal (elevated  above the clinical laboratory normal reference 
range ) at screening, a BUN will be collected to accompany the repeat creatinine. If the BUN 
is within normal range  (or less than the lower limits of normal) , then the out of range 
screening and/or repeat creatinine value will be considered NCS and subject will be  
acceptable for study inclusion  (see Appendix B for acceptable values for study eligibility) . 
8.2.[ADDRESS_1262956] prior to 
study vaccinat ion (Day 1) and on Day 29, 57, 85, 169, 197, 253, and 337 (all Treatment Arms). 
Serum from all time points  will be analyzed by [CONTACT_900630]. Serum from Day  1, 57, 85, 169 
and 197 will be analyzed by [CONTACT_900631]. Those time points  represent prior to the initial  
vaccination (Day 1), 1 month after the initial series of vaccinations (Day 57 and 85), prior to the 
six-month boost (Day 169) and [ADDRESS_1262957] (Day 197).  
8.2.4 Specimen Preparation, Handling, and Shippi[INVESTIGATOR_007]  
[IP_ADDRESS]  Instructions for Specimen Preparati on, Handling, and Storage  
Instructions for specimen preparation, handling, and storage are included in the protocol -specific 
MOP as appropriate.  
DMID #[ADDRESS_1262958] 2019  
 
  
 
DMID/NIAID/NIH           65 
CONFIDENTIAL  
 [IP_ADDRESS]  Specimen Shipment  
Specimen shipment will occur when all specimens are available following all applicable 
Intern ational Air Transport Association (IATA) requirements and according to the specifics for 
storage temperature and documentation as detailed in the local (clinical) laboratory manual and 
protocol -specific MOP as appropriate.  
 
All specimens for clinical scree ning and safety laboratory evaluations will be transported from 
the VTEU site to the local (clinical) laboratory.  
 
Specimens for cellular assays (ICS, LPA) will be transported from the VTEU site to the local 
(research) laboratory  for processing .    
 
Specimens for antibody assays (ANDV, PsVNA and PRNT) will be shipped from the VTEU site 
to the Clinical Materials Services  (CMS ). 
 
Further instructions for specimen shipment are included in the local (clinical) laboratory manual 
and protocol -specific MOP, as appropriate.  
DMID #[ADDRESS_1262959] 2019  
 
  
 
DMID/NIAID/NIH           66 
CONFIDENTIAL  
 9 ASSESSMENT OF SAFETY  
9.1 Specification of Safety Parameters  
Safety will be assessed by [CONTACT_688121]: 
1. Serious adverse events occurring from the time of study vaccination through approximately [ADDRESS_1262960] study vaccination.  
2. Solicited Adverse Events – reactogenicity events occurring from the time of study 
vaccination through 7 days after each study vaccination:  
a) Local AEs including pain, tenderness, erythema (redness), induration 
(hardness/swelling), bruising  and skin discoloration .  
b) Systemic AEs including fever, feverishness (chills, shivering, sweating), fatigue 
(tiredness), malaise (general unwell feeling), myalgia (body aches/muscular pain), 
nausea, dizziness and headache.  
3. Clinical safety laboratory adverse events occurring from the time of study vaccination 
through approximately 7 days after each study vaccination. Parameters to be evaluated 
include WBC , Hgb, platelet  count , ANC , sodium, potassium, Creatinine, total bilirubin and 
ALT.   
4. Unsolicite d Adverse Events –non-serious adverse events occurring from the time of study 
vaccination through approximately [ADDRESS_1262961] study vaccination.  
9.2 Methods and Timing for Assessing, Recording, and Analyzing Safety 
Parameters  
9.2.1 Adverse Events  
Adverse Ev ent (AE):  ICH E6 defines an AE as any untoward medical occurrence in a patient or 
clinical investigation subject administered a pharmaceutical product regardless of its causal 
relationship to the study treatment. An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease temporally associated with the 
use of a medicinal (investigational) product. The occurrence of an AE may come to the attention 
of study personnel during study visits and interv iews of a study recipi[INVESTIGATOR_710793], or upon review by a study monitor.  
DMID #[ADDRESS_1262962] 2019  
 
  
 
DMID/NIAID/NIH           67 
CONFIDENTIAL  
 AEs, including solicited local (application site) and systemic (subjective and quantitative) 
reactions, not meeting the protocol -defined criteria for SAEs will be cap tured on the appropriate 
data collection form and eCRF.  
 
Information to be collected for unsolicited non -serious AEs includes event description, date of 
onset, licensed study clinician ’s assessment of severity and relationship to study product and 
alterna te etiology (if not related to study product) (assessed only by [CONTACT_12213] a diagnosis and listed on the Form FDA 1572 as the site principal investigator 
[INVESTIGATOR_11637] -investigator), date of resolution of the event, seriousness and outcome. AEs occurring 
during the trial collection and reporting period will be documented appropriately regardless of 
relationship. AEs will be followed through resolution.  
 
Any medical condition that is present at the time that the subject is screened will be considered 
as baseline and not reported as an AE. However, if the severity of any pre -existing medical 
condition increases from the time of study vaccination through [ADDRESS_1262963] (see definitions 
below). Adverse events characterized as intermittent require documentation of onset and duration 
of each epi[INVESTIGATOR_1865]. The start and stop date of each reported AE will be reco rded on the appropriate 
data collection form and eCRF.  
 
FDA defines an AE as any untoward medical occurrence associated with the use of a drug in 
humans, whether or not considered drug related.  
 
Severity of Event:  AEs will be assessed by a licensed study clinician  listed on the Form FDA 
1572 as the site principal investigator [INVESTIGATOR_29353] -investigator using a protocol -defined 
grading system (see Section 9.2.2 ). For events not included in the protocol -defined grading 
system, the following guidelines will be used to quantify severity:  
• Mild (Grade 1) : Events require minimal or no treatment and do not interfere with the 
subject’s daily activities.  
• Moderate (Grade 2) : Events result in a low level of inconvenience or concern with 
therapeutic measures. Moderate events may cause some interference with functioning and 
daily activities.  
• Severe (Grade 3) : Events interrupt the subj ect’s daily activities and may require systemic 
drug therapy or other treatment. Severe events are usually incapacitating.  
 
DMID #[ADDRESS_1262964] 2019  
 
  
 
DMID/NIAID/NIH           [ADDRESS_1262965]:  The licensed study clinician ’s assessment of an AE's 
relationship to study product is part of the doc umentation process, but it is not a factor in 
determining what is or is not reported in this trial. If there is any doubt as to whether a clinical 
observation is an AE, the event should be reported. The relationship to study product must be 
assessed for AE s using the terms: related or not related. In a clinical trial, the study product must 
always be suspect. To help assess, the following guidelines are used:  
• Related  – There is a reasonable possibility that the study product caused the adverse event. 
Reason able possibility means that there is evidence to suggest a causal relationship between 
the study product and the adverse event.  
• Not Related  – There is not a reasonable possibility that the administration of the study 
product caused the event.  
9.2.2 Reactogenicit y  
Reactogenicity events are AEs  that are common and known to occur following administration of 
this type of study vaccine. The following Toxicity Grading Scales will be used to grade solicited 
local (application site) and systemic (subjective and quantita tive) AEs: 
Table 3:  Local (Injection Site) Reactogenicity Grading  
Local (Injection Site) 
Reaction  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Pain – experienced 
without touching the 
injection site 
(spontaneous discomfort)  Subject is aware of pain, 
but it does not interfere 
with daily activity,  and 
no pain medication is 
taken  Subject is aware of pain; 
there is interference with 
daily activity  or it 
requires repeated use of a 
non-narcotic pain reliever 
for >[ADDRESS_1262966] is aware of pain, 
and it prevents daily 
activity  or requires any use 
of a prescription medication  
Tenderness – hurts only 
when injection site is 
touched or the arm is 
moved  The area immediately 
surrounding the injection 
site hurts only when 
touched or with arm 
motion, and it does not 
interfere with daily 
activity  The area immediately 
surrounding the injection 
site hurts when touched or 
with arm motion, and it 
interferes with daily 
activity  The area immediately 
surrounding the injection 
site hurts when touched or 
with arm motion, and it 
prevents daily activity  
Erythema (Redness)*  Does not interfere with 
daily activity  Interferes with daily 
activity  Prevents daily activity  
Induration 
(Hardness/Swelling )* Does not interfere with 
daily activity  Interferes with daily 
activity  Prevents daily activity  
Skin Discoloration  Barely perceptible  Clearly discernable 
difference compared t o Unsightly difference  
DMID #[ADDRESS_1262967] 2019  
 
  
 
DMID/NIAID/NIH           69 
CONFIDENTIAL  
 Local (Injection Site) 
Reaction  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
difference compared to 
surrounding skin  surrounding skin  when compared to 
surrounding skin  
Ecchymosis (Bruising)*  Does not interfere with 
daily activity  Interferes with daily 
activity  Prevents daily activity  
Ecchymosis (bruising), erythema (redness)  and induration (hardness)/swelling as analyzed by 
[CONTACT_319679]:  
Table 4:  Local (Injection Site) Reactogenicity Measurements  
Local (Injection Site) Reaction  Small  Medium  Large  
Ecchymosis (Bruising)*  <20 mm  20 mm – 50 mm  >50 mm  
Erythema (Redness)*  <20 mm  20 mm – 50 mm  >50 mm  
Induration (Hardness)/Swelling*  <20 mm  20 mm – 50 mm  >50 mm  
* In addition to grading the measured local reaction at the greatest single diameter, they should be evaluated and 
graded using the functional scale as well as the actual measurement.  Size will  not be used as halting criteria  by 
[CONTACT_5071] . 
Table 5: Subjective Systemic Reactogenicity Grading  
Systemic (Subjective)  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Feverishness 
(chills/shivering/sweating)  noticeable but does not 
interfere with daily 
activity   interferes with daily 
activity  Significant interference in 
that it prevents daily activity  
Malaise ( General Unwell 
Feeling)  noticeable but does not 
interfere with daily 
activity   interferes with daily 
activity  Significant interference, 
prevents daily activity  
Fatigue (Tiredness)  noticeable but does not 
interfere with daily 
activity   interferes with daily 
activity  Significant interference, 
prevents daily activity  
Myalgia (Body 
Aches/Muscular Pain)*  noticeable but does not 
interfere with daily 
activity   interferes with daily 
activity  Significant interference, 
prevents daily activity  
DMID #[ADDRESS_1262968] 2019  
 
  
 
DMID/NIAID/NIH           70 
CONFIDENTIAL  
 Systemic (Subjective)  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Headache  noticeable but does not 
interfere with daily 
activity  Any use of pain reliever or 
interferes with  daily 
activity  Prevents daily activity  or 
requires  use of a 
prescription medication   
Nausea  noticeable but does not 
interfere with daily 
activity   interferes with daily 
activity  Significant interference, 
prevents daily activity  
Dizziness  noticeable but does not 
interfere with daily 
activity   interferes with daily 
activity  Significant interference, 
prevents daily activity  
* Not at injection site . 
Oral temperature# will be graded as follows:  
Table 6: Quantitative Systemic Reactogenicity Grading  
Systemic (Quantitative)  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Fever* - oral† 37.8°C – 38.4°C  
100.00°F – 101.1°F  38.5°C – 38.9°C  
101.2°F – 102.0°F  >38.9°C  
>102.0°F  
# Oral temperature assessed on Day 1 prior to study vaccination will be considered as baseline.  
* A fever can be considered not related to the study product if an alternative etiology can be documented.  
† Subjects must not eat or drink anything hot or cold, or smoke within 10 minutes prior to taking oral temperature.  
Pulse and blood pressure# will be graded as follow s: 
Table 7: Blood Pressure and Pulse Grading  
Physiologic Parameter  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Bradycardia - beats per minute  45-46 40 – 44 <40 
Tachycardia - beats per minute  106 – 130 131 – 155 >155  
Hypotension (systolic) mmHg  80 – 84 75 – 79 <75 
Hypotension (diastolic) mmHg  50 – 54 45 – 49 <45 
Hypertension (systolic) mmHg  151 – 155 156 – 160 >160  
DMID #[ADDRESS_1262969] 2019  
 
  
 
DMID/NIAID/NIH           71 
CONFIDENTIAL  
 Hypertension (diastolic) mmHg  96 – 100 101 – 105 >105  
# Pulse and blood pressure assessed on Day 1 prior to study vaccination will be considered as baseline.  
Clinical safety laboratory results# will be graded as follows:  
Table 8:  Clinical Safety Laboratory Adverse Event Grading (Hematology)  
Hematology  Clinical 
Laboratory 
Reference 
Range  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  
WBC K/mc L (Decrease , 18 to < 21 years ) 4.5 – 13.0 2.5 – 4.4 1.5 – 2.4 <1.5 
WBC K/mc L (Decrease,  ≥ 21 years)  4.5 – 11.0 2.5 – 4.4 1.5 – 2.4 <1.5 
WBC K/mc L (Increase 1 8 to < 21 years)  4.5 – 13.0 13.1 – 15.0 15.1 – 20.0 >20.0  
WBC K/mc L (Increase > 21 years ) 4.5 – 11.0 11.1 – 15.0 15.1 – 20.0 >20.0  
Hgb g/dL (Decrease) (Female)   11.7 – 15.7 10.1 – 11.6 8.5 – 10 <8.5 
Hgb g/dL (Decrease) (Male)  13.3 – 17.7 11.0 – 13.2 9.5 – 10.9 <9.5 
Platelet  count  K/mc L (Decrease)  135 - 466 125 – 134 100 – 124 <100  
Platelet  count  K/mc L (Increase)  135 - 466 467 - 517 518 – 750 >750  
Absolute Neutrophil Count, K/mcL * (18 to 
< 21 years ) 1.80 – 8.00 1.5-<1.8 1.0-<1.5 <1.0 
Absolute Neutrophil Count, K/mc L* (≥ 21 
years)  1.80 – 7.70 1.5-<1.8 1.0-<1.5 <1.0 
Absolute Neutrophil Count, K/mcL  - 
Benign Ethnic Neutropenia*  > 0.8 0.6 – 0.7 0.4 – 0.5 < 0.4  
*  ANC for subjects that are of African American and Middle Eastern de scent may have values as low as 0.8  K/mcL . 
Subjects of this de scent must have an ANC ≥ 0.8 K/mcL  to be eligible to participate in the study if all other study 
criteria are met.    
Table 9: Clinical Safety Laboratory Adverse Event Grading (Chemistry)  
Chemistry  Clinical 
Laboratory 
Reference 
Range  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  
ALT unit/L (Increase)  ≤49 50-123 124-245 > 245 
DMID #[ADDRESS_1262970] 2019  
 
  
 
DMID/NIAID/NIH           72 
CONFIDENTIAL  
 Total Bilirubin mg/dL (Increase) – when 
accompanied by [CONTACT_295632]  0.10 – 1.2 1.3 – 1.5 1.6 – 1.8 >1.8 
Total Bilirubin mg/dL (Increase) – when 
ALT is normal  0.10 – 1.2 1.3 – 1.8 1.9 – 2.4 >2.4 
Creatinine mg/dL (Increase) (Female)  0.50 – 0.80 0.81 – 1.70 1.71 – 2.00 >2.00  
Creatinine mg/dL (Increase) (Male)  0.60 – 1.10 1.11 – 1.70 1.71 – 2.00 >2.00  
Sodium, low, m mol/L 136 – 145 130 - 135 123-129 <123  
Sodium, high, m mol/L 136 - 145 146 - 150 151-157 >157  
Potassium, high, m mol/L 3.5 – 5.1 5.2 - 6.0 6.1-6.5 >6.5 
Potassium, low, m mol/L 3.5 – 5.1 3.0 - 3.4 2.5-2.9 <2.5  
Blood Urea Nitrogen (BUN) mg/dL  9.00 – 23.00 24 – 26 27 - 31 >31 
# Clinical laboratory evaluations assessed at the Day 1  visit will be considered as baseline.  
9.2.3 Serious Adverse Events  
Serious Adverse Event (SAE) : An adverse event or suspected adverse reacti on is considered 
“serious” if, in the view of either the site principal investigator [INVESTIGATOR_10157], it results in any of the 
following outcomes:  
• death,  
• a life -threatening adverse event*,  
• inpatient hospi[INVESTIGATOR_1081],  
• a persistent or significant incapacity or substantial disruption of the ability to conduct normal 
life functions, or  
• a congenital anomaly/birth defect.  
• Important medical events that may not result in death, be life-threatening, or require 
hospi[INVESTIGATOR_12190], based upon appropriate medical judgment 
they may jeopardize the patient or subject and may require medical or surgical intervention to 
prevent one of the outcomes listed in this definition. Examples of such medical events 
include allergic bronchospasm requiring intensive treatment in an emergency room or at 
home, blood dyscrasias or convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the 
development of drug dependency or drug abuse.  
DMID #[ADDRESS_1262971] 2019  
 
  
 
DMID/NIAID/NIH           73 
CONFIDENTIAL  
 *  Life-threatening adverse event. An adverse event is considered “life -threatening” if, in the view of 
either the site principal investigator [INVESTIGATOR_10157], its occurrence places the subject at immediate risk of 
death. It does not include an a dverse event that, had it occurred in a more severe form, might have 
caused death.  
SAEs will be:  
• Assessed for severity and relationship to study product and alternate etiology (if not 
related to study product) by a licensed study physician  listed on the Fo rm FDA 1572 as 
the site principal investigator [INVESTIGATOR_11637] -investigator.  
• Recorded on the appropriate SAE form and eCRF.  
• Followed through resolution by a licensed study physician  listed on the Form FDA 1572 
as the site principal investigator [INVESTIGATOR_11637] -investigator.  
• Reviewed and evaluated by [CONTACT_202421] (ISM) (as deemed necessary), 
the SMC (periodic review unless related), DMID, and the IRB.  
9.2.[ADDRESS_1262972] Values or 
Abnormal Clinical Findings  
The s ite principal investigator [INVESTIGATOR_29353] -investigator is responsible for recording all 
AE/SAEs that are observed or reported during this trial, regardless of the relationship to study 
product.  AE/SAEs, abnormal laboratory test values, or abnormal clin ical findings will be 
collected, assessed, documented, reported, and followed appropriately.  
 
For baseline laboratory results that are abnormal according to the local laboratory reference 
range  and fall within Grade 1 toxicity table range, these will not b e considered laboratory 
adverse event (AE) and will thus not be graded.   However, if baseline clinical labs fall within 
Grade 1 range, then a laboratory AE is reported only if the value changes such that it falls into 
Grade 2 or higher when subsequent saf ety laboratory testing is done.  
9.3 Reporting Procedures  
Solicited local  and systemic AEs will be documented and reported from the time of study 
vaccination through 7 days after each study vaccination.  
DMID #[ADDRESS_1262973] 2019  
 
  
 
DMID/NIAID/NIH           [ADDRESS_1262974] study vaccination.  
SAEs (including lab values that meet SAE criteria) will be documented and reported from the 
time of study vaccination through approximately [ADDRESS_1262975] be submitted immediately (within 24 
hours of site awareness) on an SAE form to the DMID Pharmacovigilance Group at the 
following address:  
DMID Pharmacovigilance Group  
Clinical Research Operations and Management Support (CROMS)  
[ADDRESS_1262976]. Suite  650 
Bethesda, MD [ZIP_CODE], [LOCATION_003]  
SAE Hot Line: 1 -[PHONE_889] (US) or 1 -[PHONE_1728] (outside US)  
SAE FAX: 1 -[PHONE_1729] (US) or 1 -[PHONE_891] (outside US)  
SAE Email Address: [EMAIL_1393]  
In addition to the SAE form, selected SAE data fields must also be entered into Advantage 
eClinicalSM. Please see the protocol -specific MOP for details regardin g this procedure.  
Other supporting documentation of the event may be requested by [CONTACT_154385].  
The site will send a copy of the SAE report(s) to the ISM (as deemed necessary) when they are 
provided to the DMID Pharmacovigilance Group.  The DMID Medical Monitor and DMID 
Clinical Project Manager will be notified of the SAE by [CONTACT_71500].  
DMID #[ADDRESS_1262977] 2019  
 
  
 
DMID/NIAID/NIH           [ADDRESS_1262978].  
9.3.2 Regulatory Reporting for Studies Conducted Under DMID -Sponsored IND  
Following notification from the site principal investigator [INVESTIGATOR_29353] -investigator , 
DMID, the Investigational New Drug ( IND) sponsor, will report any suspected adverse reaction 
that is both serious and unexpected.  DMID will report an adverse event as a suspected adverse 
reaction only if there is evidence to suggest a causal relationship between the drug and the 
adverse even t. DMID will notify FDA and the site principal investigators (i.e., all principal 
investigators to whom the sponsor is providing drug under its IND(s) or under any principal 
investigator’s IND(s)) in an IND safety report of potential serious risks from cli nical trials or any 
other source, as soon as possible, but in no case later than 15 calendar days after the sponsor 
determines that the information qualifies for reporting as specified in 21 CFR Part 312.32.  DMID 
will also notify FDA of any unexpected fata l or life -threatening suspected adverse reaction as 
soon as possible, but in no case later than 7 calendar days after the sponsor’s initial receipt of the 
information.  Relevant follow up information to an IND safety report will be submitted as soon as 
the information is available.  Upon request from FDA, DMID will submit to FDA any additional 
data or information that the agency deems necessary, as soon as possible, but in no case later 
than [ADDRESS_1262979].  
All serious events des ignated as “not related” to study product(s), will be reported to the FDA at 
least annually in a summary format.  
9.3.[ADDRESS_1262980]’s permission , all protocol -required venous blood 
samples will be obtained and the subject will continue to be followed for safety for the duration 
of this trial . Efforts will be made to follow all pregnancies  reported during the course of this trial 
to pregnancy outcome pending the subject’s permission.  
9.[ADDRESS_1262981] study vaccination.  
DMID #[ADDRESS_1262982] 2019  
 
  
 
DMID/NIAID/NIH           76 
CONFIDENTIAL  
 SAEs will  be collected, assessed, and followed from  the time of study vaccination through  
resolution even if this extends beyond the trial -reporting period (approximately [ADDRESS_1262983] study vaccination).  
Resolution of an AE/SAE is defined as the return to pretreatment status or stabilization of the 
condition with the expectation that it will remain chronic.  
If the site principal investigator [INVESTIGATOR_29353]-investigator  becomes aware of an acute 
febrile illness and the site principal investigator [INVESTIGATOR_29353] -investigator  decides to bring 
the subject in for an evaluation to determine etiology, then the site principal investigator [INVESTIGATOR_168702] -investigator , at their own discretion, can determine if specific viral testing should 
be done by [CONTACT_900632] . 
Follow -up procedures, evaluations, and outcomes will be recorded on the appropriate data 
collection form.  
9.[ADDRESS_1262984] Halting Rules  
If any of these conditions are met, further vaccinations will be halted pending SMC electronic 
review.  
[IP_ADDRESS]  If none of the following conditions are met, may proceed to the second sentinel subject : 
• Any SAE regardless of the relationship to the study product  
• Any laryngospasm, bronchospasm, or anaphylaxis within [ADDRESS_1262985].  
• One Grade [ADDRESS_1262986].  
[IP_ADDRESS]  If none of the following conditions are met, may proceed to the r emainder of the cohort:  
• Any SAE regardless of the relationship to the study product  
• Any laryngospasm, bronchospasm, or anaphylaxis within [ADDRESS_1262987].  
• Any generalized urticaria after administration of study product that is considered related to 
study product.  
DMID #[ADDRESS_1262988] 2019  
 
  
 
DMID/NIAID/NIH           77 
CONFIDENTIAL  
 • One Grade [ADDRESS_1262989]  and not 
resolved o r improved to lower grade within 2 days . 
• Same  Grade [ADDRESS_1262990]  and not resolved or improved to lower grade within 2 
days. 
• Same  Grade [ADDRESS_1262991]  and not resolved or improved to lower grade within 2 
days. 
• Same  Grade [ADDRESS_1262992].  
9.5.2 Study Halting Rules  
Further enrollment and study vaccinations will be halted for SMC review/recommendation if any 
of the following are reported:  
• Any subject experiences a study product -related SAE from the time of the study product  
administration through the subject’s last study visit.  
• Any subject experiences laryngospasm, bronchospasm, or anaphylaxis within [ADDRESS_1262993].  
• Two or more subjects experience gener alized urticaria (defined as occurring at more than two 
body parts) after administration of study product that is considered related to study product.  
• Two or more subjects experience a grade 3 unsolicited AE (in the same MedDRA High 
Level Term) after administration of study product that is considered related to study product 
and not resolved or improved to lower grade within 2 days.  
This trial  will also be halted for SMC  review/recommendation if, within 7 days after 
administration of any study vaccinat ion, any of the following occurs:  
• Two or more subjects experience the same grade [ADDRESS_1262994] and not resolved or improved to lower grade within 2 
days. 
• Two or more subjects experience the same  grade [ADDRESS_1262995]  and not resolved or improved to lower grade within 2 
days. 
DMID #[ADDRESS_1262996] 2019  
 
  
 
DMID/NIAID/NIH           78 
CONFIDENTIAL  
 • Two or more subjects experience the same grade [ADDRESS_1262997].  
Grading scales for solicited local (application site) and systemic (subjective and quantitative) 
AEs are included in Section 9.2.[ADDRESS_1262998] receipt of any study vaccinati on, then 
this trial will not continue with the remaining enrollments or study vaccinations without a review 
by [CONTACT_319680].  
DMID retains the authority to suspend additional enr ollment and study interventions/ 
administration o f study product during the entire trial, as applicable.  
9.6 Safety Oversight  (ISM plus SMC ) 
9.6.1 Independent Safety Monitor  (ISM)  
An ISM is a physician with relevant expertise whose primary responsibility is to provide to 
DMID an independent safety assessment in a timely fashion. Participation is for the duration of 
the DMID study and is a voluntary position that does not receive payment. The ISM must meet 
the requirements of the NIAID conflict of interest policy.    
The ISM:  
• Is in close proximity to the study site a nd has the authority and ability to readily access 
study participant records in real time.  
• May be a member of the participating institution’s staff but preferably be from a different 
organizational group within the institution.  
• Should not be in a direct supervisory relationship with the investigator.  
• Should have no direct involvement in the conduct of the study.  
The ISM will:  
• Sign a Conflict of Interest (COI) certification at the time they are asked to participate and 
provide updates to th is information as needed.  
• Receive reports of Serious Adverse Events (SAEs) from the site investigator and will be 
notified by [CONTACT_295052].  
DMID #[ADDRESS_1262999] 2019  
 
  
 
DMID/NIAID/NIH           79 
CONFIDENTIAL  
 • Evaluate the SAE and report their clinical assessment to DMID, through DMID -CROMS 
SOCS in a timely manner using the attached report form and email the report to DMID -
CROMS SOCS.   
• Communicate with the investigator at the site as needed.  
• Review additional s afety related events at the request of DMID.  
• Provide additional information to DMID and/or the SMC by [CONTACT_319681].  
9.6.2 Safety Monitoring Committee (SMC)  
This clinical study will utilize an SMC, which is an independent group of experts that advi ses 
DMID. The primary responsibility of the SMC is to monitor subject safety. The SMC is external 
to the DMID and comprises at least [ADDRESS_1263000] -free basis independently of the study t eam. The DMID or the SMC may convene ad hoc 
meetings of the SMC according to protocol criteria or if there are concerns that arise during the 
study.  
 
The SMC will review the safety data at the following milestones:  
• Organizational meeting (prior to start of  the study)   
• Data Review meeting (DRM)  will be held  if any sentinel halting rules are met  for Cohort  [ADDRESS_1263001] 2 sentinel subjects in Cohort s 1 and 2 (2 mg d ose group) that have completed [ADDRESS_1263002]. No new subjects may be enrolled 
during this follow -up and review period, but screening may continue.   
• DRM: The SMC will conduct a review of available safety data  for the first 24 subjects in 
Cohort 1  and 2 (2 mg dose  group)  that have completed [ADDRESS_1263003] . No new subjects may be enrolled during this 
follow -up and review period, but screening for Cohort 3 and 4 and vaccination of the 
remaining doses in Cohort s 1 and 2 may continue.   
• DRM  will be held  if any sentinel halting rules are met  for the Cohort [ADDRESS_1263004] 2 
sentinel subjects in Cohort 3 and 4 (4 mg dose group) that have completed [ADDRESS_1263005]. No new subjects may be enrolled during this 
follow -up and review perio d, but screening may continue.   
DMID #[ADDRESS_1263006] 2019  
 
  
 
DMID/NIAID/NIH           80 
CONFIDENTIAL  
 • An Ad Hoc meeting will be convened when a halting rule is met, or at the request of the 
investigator and/or DMID if there are safety concerns during the course of the study.  
• Final review meeting: approximately [ADDRESS_1263007] summary format. The SMC may be asked to provide 
recommendations in response to questions posed by [CONTACT_122830].  
The SMC will operate under the rules of a DMID -approved charter that will be written at the 
organizational meeting of the SMC. At this time, each data element that the SMC needs to assess 
will be clearly defined. Procedures for SMC reviews/meetings will be def ined in the charter. The 
SMC will review applicable data to include, but not limited to, study progress and participant 
clinical, safety, and reactogenicity data. Reports may include enrollment and demographic 
information, medical history, concomitant medi cations, physical assessments, clinical laboratory 
values, dosing compliance, and solicited and unsolicited AE/SAEs. Additional data may be 
requested by [CONTACT_4484], and interim statistical reports may be generated as deemed necessary and 
appropriate by [CONTACT_122830]. The SMC may receive data in aggregate and presented by [CONTACT_9084]. The 
SMC may also be provided with expected and observed rates of the expected AEs in an 
unblinded fashion, and may request the treatment assignment be unblinded for an individual 
subject if req uired for safety assessment. The SMC will review grouped and unblinded data in 
the closed session only. The SMC will meet and review this data at scheduled time points or ad 
hoc as needed during this trial as defined in the SMC charter. As an outcome of ea ch 
review/meeting, the SMC will make a recommendation as to the advisability of proceeding with 
study vaccinations (as applicable), and to continue, modify, or terminate this trial.  
DMID or the SMC chair may convene the SMC on an ad hoc basis according to protocol criteria 
or if there are immediate concerns regarding observations during the course of this trial. The 
DMID Medical Monitor is empowered to stop enrollment and study vaccinations if adverse 
events that meet the halting criteria are reported. The DMID Medical Monitor and the ISM (as 
deemed necessary) will be responsible for reviewing SAEs in real time. The SMC will review 
SAEs on a regular basis and ad hoc during this trial.  
DMID #[ADDRESS_1263008] 2019  
 
  
 
DMID/NIAID/NIH           81 
CONFIDENTIAL  
 10 CLINICAL MONITORING  
10.1 Site Monitoring Plan  
Site monitoring is conducted to e nsure that the human subjects’ protections, study and laboratory 
procedures, study intervention administration, and data collection processes are of high quality 
and meet sponsor, ICH/GCP guidelines and applicable regulations, and that this trial is 
conduc ted in accordance with the protocol, protocol -specific MOP and applicable sponsor SOPs . 
DMID, the sponsoring agency, or its designee will conduct site -monitoring visits as detailed in 
the clinical monitoring plan.  
Site visits will be made at standard inter vals as defined by [CONTACT_149098]. Monitoring visits will include, but are not limited to, review of 
regulatory files, accountability records, eCRFs, ICFs, medical and laboratory reports, and 
protocol and GCP compl iance. Site monitors will have access to the VTEU site, study personnel, 
and all study documentation according to the DMID -approved site monitoring plan. Study 
monitors will meet with site principal investigators to discuss any problems and actions to be 
taken and document visit findings and discussions.  
DMID #[ADDRESS_1263009] 2019  
 
  
 
DMID/NIAID/NIH           [ADDRESS_1263010] a specific hypothesis. Rather, it is intended to obtain preliminary estimates in 
healthy adults of the safety, reactogenicity, and immunogenicity of the ANDV vaccine in healthy 
adults.  
11.2 Sample Size Considerations   
Rare adverse events are not demonstrable in a clinical study of this size; howev er, the 
probabilities of observing one or more AEs given various true event rates are presented in  Table 
10. 
Table 10: Probabil ity of Observing an Adverse Event for Various Event Rates  
N "True" Event 
Rate  Probability of 
Observation (%)  N "True" Event 
Rate  Probability of 
Observation (%)  
10 0.1%  1.0 
20 0.1%  2.0 
0.5%  4.9 0.5%  9.5 
1.0%  9.6 1.0%  18.2 
2.0%  18.3 2.0%  33.2 
3.0%  26.3 3.0%  45.6 
4.0%  33.5 4.0%  55.8 
5.0%  40.1 5.0%  64.2 
10.0%  65.1 10.0%  87.8 
20.0%  89.3 20.0%  98.8 
11.3 Planned Interim Analyses (if applicable)  
11.3.1  Interim Safety Review  
After the completion of enrolling 24 subjects in Cohorts 1  and 2 (2 mg dose group), the SMC 
will review the data for Cohorts [ADDRESS_1263011] the second vaccination .  
These reviews, however, may not involve any hypothesis testing and will not be considered in 
estimating the precision of any estimates made a t the conclusion of the study.  
DMID #[ADDRESS_1263012] 2019  
 
  
 
DMID/NIAID/NIH           83 
CONFIDENTIAL  
 11.3.2  Interim Analysis of Safety and Immunogenicity Data  
An interim analysis of safety, reactogenicity, and immuno logic  response data  (excluding 
exploratory outcomes)  is planned once all subjects (Cohort 1 -4) have completed the Day [ADDRESS_1263013] on Type I error and adjustments are not planned.  
11.4 Final Analysis Plan  
The final analysis will be perform ed and clinical study report completed when all primary safety 
endpoint data and all secondary immunogenicity endpoint data are available. The interim 
analysis based on the primary clinical data base will be included in the final clinical study report 
(CSR ). The CSR will be completed after the final data lock (through approximately Day 337 
follow -up) and when all primary endpoint data are received by [CONTACT_900633]. Any available data from 
the exploratory immunogenicity endpoints may also be included or if agreed upo n, in an 
addendum to the CSR . A formal statistical analysis plan will be developed by [CONTACT_900634].  
11.4.1  Analysis Populations  
The Safety Analysis population includes all subjects who received one dose of study vaccine.  
The i ntent -to-treat (ITT) population includes all subjects who received one dose of  study vaccine 
and contributed both pre - and at least one post -study vaccination venous blood samples for 
immunogenicity testing for which valid results were reported. For analys es using the ITT 
population, subjects will be grouped based on randomized treatment arm.   
DMID #[ADDRESS_1263014] 2019  
 
  
 
DMID/NIAID/NIH           84 
CONFIDENTIAL  
 In the final analysis, if there are major protocol deviations, a per -protocol (PP) analysis may be 
performed. The per protocol (PP) population includes all subjects in the ITT subset with the 
following exclusions:  
• Data from all available visits for subjects found to be ineligible at baseline.  
• Data from all visits subsequent to major protocol deviations, such as:  
• Receipt of non -study  licensed live vaccine within 28 days before or after study 
vaccination,  
• Receipt of non -study licensed inactivated vaccine within 14 days before or after study 
vaccination,*  
*Allowable exception for inactivated seasonal influenza vaccine received more than 7 days prior 
to or after a study vaccination.  
• Receipt of immunosuppressive therapy (e.g., corticosteroids) within 30 days before or 
after study vaccination.  
• Data from any visit that occurs substantially out of window.  
For analyses using the PP population, subjects will be grouped ba sed on study vaccinations 
received.  
11.4.2  Safety Data  
Summaries and analysis of safety data will be presented for the Safety Analysis Population.  
Solicited AEs will be summarized by [CONTACT_900635] (Days [ADDRESS_1263015] 
study vaccination) and as  the maximum severity over all [ADDRESS_1263016] severe response over the follow -up period, dichotomizing into a 
binary variable (none versus mild, moderate, or severe) and using standard techniques, su ch as 
exact confidence intervals (CI), to summarize the proportion of subjects reporting each symptom, 
any application site symptom, and any systemic symptom.  
Unsolicited non -serious AEs will be collected from the time of first study vaccination through 
approximately [ADDRESS_1263017] vaccination . Unsolicited AEs will be coded by [CONTACT_3772] (MedDRA) for preferred term and system organ class 
(SOC). SAEs will be collected from the time of first study va ccination through approximately [ADDRESS_1263018] Apreferred term and SOC, 
relevant dates (study vaccinati ons and AEs), severity, relatedness, and outcome for each event. 
DMID #[ADDRESS_1263019] 2019  
 
  
 
DMID/NIAID/NIH           [ADDRESS_1263020] one event in each MedDRApreferred term and SOC, cross tabulated by [CONTACT_900636]. Additionally, the proportion of subjects and exact 95% confidence 
intervals of AEs in aggregate and by [CONTACT_61132]categories will be computed.  
Clinical laboratory data will be summarized by [CONTACT_394447], and as the maximum ov er 
all post -study vaccination visits. Graphical presentations may include box plots and shift plots.  
11.4.3  Immunogenicity Data  
[IP_ADDRESS]    Cellular Assays (ICS, LPA)  
Summaries and analysis of cellular assay data will be presented for the ITT population. If there 
are majo r protocol deviations, a per -protocol (PP) analysis may also be performed.  
 
Immune responses in terms of incidence  of a cellular immune response to ANDV peptide pool 
>[ADDRESS_1263021] deviations (SD) above that on Day  1 will be summarized. Cellular responses wil l be 
measured by [CONTACT_900637] -secreting CD4+ and CD8+ T Cell responses and mean 
CD4+ and CD8+ T Cell lymphoproliferation. Analyses will include response (>3 SD) for the 
different groups at the different time points.  
[IP_ADDRESS]    Immunogenicity ( PsVNA , PRNT)  
Summaries and analysis of immunogenicity data will be presented for the ITT population. If 
there are major protocol deviations, a per -protocol (PP) analysis may also be performed.  
Immune responses in terms of a titer > [ADDRESS_1263022] of including or excluding the outliers. Any substantive differences in these analyses will 
be reported.  
DMID #[ADDRESS_1263023] 2019  
 
  
 
DMID/NIAID/NIH           86 
CONFIDENTIAL  
 12 SOURCE DOCUMENTS AND ACCESS TO SOURCE 
DATA/DOCUMENTS  
The study  site will maintain appropriate medical and research records for th is trial, in compliance 
with ICH E6, Section 4.9, and regulatory and institutional requirements for the protection of 
confidentiality of subjects. The study  site will permit authorized representatives of DMID, its 
designees, and appropriate regulatory agen cies to examine (and when required by [CONTACT_1289], 
to copy) clinical trial records for the purposes of quality assurance reviews, audits, monitoring 
and evaluation of the study safety and progress. These representatives will be permitted access to 
all source data, which include, but are not limited to, hospi[INVESTIGATOR_1097], clinical and office charts, 
laboratory notes, memoranda, evaluation checklists, pharmacy dispensing records, recorded data 
from automated instruments, copi[INVESTIGATOR_233702] a fter verification as being accurate 
and complete, microfiches, photographic negatives, microfilm or magnetic media, x -rays, and 
subject files and records kept at the pharmacy, at the laboratories, and medico -technical 
departments involved in the trial. Sou rce data are all information, original records of clinical 
findings, observations, or other activities in a clinical trial necessary for the reconstruction and 
evaluation of the trial.  
 
Interview of subjects is sufficient for obtaining medical history. Sol icitation of medical records 
from the subject’s primary care provider is not required unless deemed needed  by [CONTACT_3786] . Data collection forms for use as source documents will be derived from the CRFs 
and be provided by [CONTACT_80938].  Supplemental site -specific source documents may be included as 
appropriate.  
DMID #[ADDRESS_1263024] 2019  
 
  
 
DMID/NIAID/NIH           87 
CONFIDENTIAL  
 13 QUALITY CONTROL AND QUALITY ASSURANCE  
Following a written DMID -accepted site quality management plan, the site is responsible for 
conducting routine quality assurance (QA) and quality control (QC) ac tivities to internally 
monitor study progress and protocol compliance. Each site principal investigator [INVESTIGATOR_900591]’s study -related source data/data collection forms, and reports for the 
purpose of monitoring and auditing by [CONTACT_456], and inspection by [CONTACT_90471]. Each site principal investigator [INVESTIGATOR_900592].  
 
The SDCC will implement quality control p rocedures beginning with the data entry system and 
generate data quality control checks that will be run on the database. Any missing data or data 
anomalies will be communicated to the site for clarification and resolution.  
DMID #[ADDRESS_1263025] 2019  
 
  
 
DMID/NIAID/NIH           88 
CONFIDENTIAL  
 14 ETHICS/PROTECTION OF HUMAN SUBJE CTS  
14.[ADDRESS_1263026]  
The site principal investigator [INVESTIGATOR_710800]: Ethical Principles and Guidelines for the Protection of Human 
Subjects of Research of the National Commi ssion for the Protection of Human Subjects of 
Biomedical and Behavioral Research (April 18, 1979) and codified in 45 CFR 46, 21 CFR 50 
and 56, and ICH E6; 62 Federal Regulations [ZIP_CODE] (1997), if applicable. The site principal 
investigator’s institution wil l hold a current Federalwide Assurance (FWA) issued by [CONTACT_466603] (OHRP) for federally funded research.  
14.[ADDRESS_1263027] 
informed consent process before conducting protocol -specific scree ning activities.  
DMID #[ADDRESS_1263028] 2019  
 
  
 
DMID/NIAID/NIH           89 
CONFIDENTIAL  
 Informed consent is a process that is initiated prior to an individual agreeing to participate in a 
trial and continuing throughout the individual’s trial participation. Before any study procedures 
are performed, including pre -screening of  subjects for eligibility, subjects will receive a 
comprehensive explanation of the proposed study procedures and study interventions/products. 
This will include the nature, risks and possible benefits of this trial, alternate therapi[INVESTIGATOR_014], any 
known AEs, the  investigational status of the study interventions/products, and the other elements 
that are part of obtaining proper informed consent. Subjects will also receive a detailed 
explanation of the proposed use and disclosure of their protected health informati on, including 
specifically their serum samples. Subjects will be allowed sufficient time to consider 
participation in this research trial, after having the nature, risks and possible benefits of this trial 
explained to them, and have the opportunity to dis cuss this trial with their family, friends or 
legally authorized representative, or think about it prior to agreeing to participate.  
ICFs describing in detail the study interventions/products, study procedures, risks and possible 
benefits will be given to subjects. The ICF must not include any exculpatory statements. ICFs 
will be IRB -approved and subjects will be asked to read and review the appropriate document. 
Upon reviewing the appropriate document, the site principal investigator (or designee) will 
explain this research trial to subjects and answer any questions that may arise. Subjects must sign 
the ICF, and written documentation of the informed consent process is required prior to starting 
any study procedures being done specifically for this trial, i ncluding determining eligibility and 
administering study product.  
By [CONTACT_12568], subjects agree to complete all study procedures required by [CONTACT_429794], unless 
the subject withdraws voluntarily, or is withdrawn or terminated from this trial for any re ason. 
The rights and welfare of subjects will be protected by [CONTACT_900638].  
DMID will provide the site principal investigator, in writing, any new information that 
significantly impacts the subject’s risk of receiving the investigational products. This new 
information will be communicated by [CONTACT_16541] [INVESTIGATOR_900593]. The informed consent document 
will be updated and subjects will be re -consented per IRB requirements, if necessary. Subjects 
will be given a copy of all ICFs that they sign.  
DMID #[ADDRESS_1263029] 2019  
 
  
 
DMID/NIAID/NIH           90 
CONFIDENTIAL  
 14.4 Exclusion of Women, Minorities, and Children (Special Populations)  
This trial will be inclusive of all adults who meet the Subject Inclusion Criteria (see Section 5.1) 
and do not meet the Subject Excl usion Criteria (see Section 5.2), regardless  of religion, sex, or 
ethnic background. Should the outcome of this trial be deemed acceptable, additional trials may 
be initiated including those in other populations. Children  will not be included in this trial  as they 
are not the target population at this time . 
14.[ADDRESS_1263030] party without prior written approval  of the sponsor.  
All information provided by [CONTACT_900639] (other than a subject’s medical records) will be kept confidential by [CONTACT_900640]. This 
information and data will not be used by [CONTACT_900641]. These restrictions do not apply to: (1) 
information which beco mes publicly available through no fault of the site principal investigators 
or other study personnel; (2) information which is necessary to disclose in confidence to an IRB 
solely for the evaluation of this trial (3) information which is necessary to discl ose in order to 
provide appropriate medical care to a study subject; or (4) study results which may be published 
as described in Section 16.  
In addition,  this research is covered by a Certificate of Confidentiality from the NIH. The 
investigators and their staff may not disclose or use information documents, or biospecimens that 
may identify the subjects in any federal, state, or local civil, criminal, administr ative, legislative 
or other action, or be used as evidence unless the subject has consented. This does not apply to 
requests for information from the NIH or its representatives that are needed to monitor or audit 
the study, or for information that must be disclosed in order to meet FDA requirements.  
DMID #[ADDRESS_1263031] 2019  
 
  
 
DMID/NIAID/NIH           [ADDRESS_1263032] all documents and records required to be maintained 
by [CONTACT_900642]. This includes, but is not limited to, medical records (office, 
clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the subjects in this trial. The  VTEU site will permit 
access to such records.  
14.[ADDRESS_1263033] signed the ICF and are randomized and 
vaccinated, will continue to be followed for safety for the duration of this trial. No further study 
vaccinations will be administered.  
14.7 Future Use of Stored Specimens  and Data  
Residual samples  are those that are left over after the study has been completed  and are stored 
for possible use in future research studies . Future use samples are extra tube/s of blood collected 
and stored for possible use in future research studies. Retention of residual samples f or future use 
and the collection and storage of samples for use in future research studies is a condition of study 
participation.  Subjects who sign the informed consent form for the study  are consent ing to allow 
the collection, storage and use of both res idual and future use samples.   
Residual samples (serum or cells) derived from venous blood samples will be maintained for 
possible use in future research studies, such as examining additional immunological assessments 
or testing for antibodies against othe r viruses or bacteria. These  samples may be shared for 
purposes other than per protocol analysis with investigators at the participating VTEU site and 
with other investigators at other institutions once the clinical study report has been finalized.    
Futur e use samples ( whole blood, serum or cells ) will be collected at Day 85, 197 and 337 . It is 
anticipated that approximately two to five aliquots of serum ( 4 ml/each) from venous blood 
samples will be available specifically for the purpose of future research at Day 85, 197 and 337 . 
PBMCs collected at day 337 will also be processed for future use . Future use research studies 
may include but are not limited to non -traditional immune assay development, assessing innate 
immune factors, cytokines and other virologic evaluations  and Human Leukocyte Antigen 
(HLA) testing to explore the impact of host genetics on immune responses to ANDV DNA 
vaccine. If HLA testing is performed, resu lts will be part of research records and will not become 
part of a subject’s medical record and will not be shared with their doctor.   
DMID #[ADDRESS_1263034] 2019  
 
  
 
DMID/NIAID/NIH           [ADDRESS_1263035]. Genetic tests may be performed on samples. Each sample will be 
encoded (labeled) only with a barcode and a unique tracking number to protect subject 
confidentiality. There are no benefits to subjects in the collection, storage and subsequent use of 
their specimens for future research. Reports about future research done with subjects’ samples 
will NOT be kept in their health records.  
Residual samples will be available upon the completion of the study; however, future use 
samples may be requested from DMID and shipped from the DMID CMS at any time.  
Subjects may change  their decision to participate in the study at any time by [CONTACT_90475]. However,  any data from a previously collected sample prior to the 
withdrawn consent will not be removed . Any future use of residual samples or collecti on of 
samples sp ecifically for future research not yet collected/stored will not be stored for 
future/residual use. Any data from a previously collected sample prior to the withdrawn consent 
will not be removed.  
DMID #[ADDRESS_1263036] 2019  
 
  
 
DMID/NIAID/NIH           [ADDRESS_1263037] enrolled in  this trial. All data collection forms should be 
completed in a neat, legible manner to ensure accurate interpretation of data. Black or blue ink is 
required to ensure clarity of reproduced copi[INVESTIGATOR_014]. When making a change or correction, cross out 
the original  entry with a single line and initial and date the change. Do not erase, overwrite, or 
use correction fluid or tape on the original.  
Data reported in the eCRF derived from the data collection forms should be consistent with the 
data collection forms or the  discrepancies should be explained.  
The sponsor and/or its designee will provide guidance to the site principal investigators and other 
study personnel on making corrections to the data collection forms and eCRF.  
15.[ADDRESS_1263038] maintain complete and accurate documentation for this trial.  
The SDCC for this trial will be responsible for data management, quality review, analysis, and 
reporting of the study data.  
15.2 Data Capture Methods  
Clinical (including, but not limited to, AE/SAEs, concomitant medications, medical history, 
physical assessments, and clinical laboratory values), reactogenicity, and immunogenicity data 
will be entered into a [ADDRESS_1263039] protection and internal quality checks, such as automatic 
DMID #[ADDRESS_1263040] 2019  
 
  
 
DMID/NIAID/NIH           94 
CONFIDENTIAL  
 range checks, to identify data that appear inconsistent, incomplete, or inaccurate. Clinical and 
reactogenicity data will b e entered directly from the data collection forms completed by [CONTACT_71510].  
15.3 Types of Data  
Data for this trial will include clinical, safety, and outcome measures (e .g., clinical laboratory 
values,  reactogenicity, and immunogenicity data).  
15.4 Timing/Re ports  
See Section 9.[ADDRESS_1263041] and DMID approval, the SDCC may provide the study 
team with interim summary results for purposes of designing future trials or for 
publication/presentation of the data. Safety and immunogenicity summary reports may be 
generated for the SMC.  
After full analysis and final reporting is complete, and upon request and DMID approval, the 
SDCC will provide the VTEU site with a summary of results by [CONTACT_692346]/or subject 
treatment assignments. In this regard, the VTEU site requesting such information to share with 
study subjects must do so in compliance with their respective IRB guidelines.  
15.5 Study Records Retention  
Study records and reports including, but not limited to, eCRFs, source documents, ICFs, and 
study drug disposition records shall be maintained for 2 years after a marketing application is 
approved for the drug for the indication for which it is being investigated; or, if no application is 
to be filed or if the application is not approved for the drug, until [ADDRESS_1263042] DMID for authorization prior to the destruction of any study 
records.  
DMID #[ADDRESS_1263043] 2019  
 
  
 
DMID/NIAID/NIH           [ADDRESS_1263044], the site 
principal investigator, or other study personnel. As a result of deviations, c orrective actions are 
to be developed by [CONTACT_3483].  
These practices are consistent with ICH E6:  
4.[ADDRESS_1263045] be promptly reported to DMID, via the SDCC’s Advantage 
eClinicalSM. 
All protocol deviations, as defined above, must be addressed in study subject data collection 
forms. A completed copy of the DMID Protocol Deviation Form must be maintained in the 
Regulatory File as well as in the subject’s chart. Protocol deviations must be sent to the local 
IRB per its guidelines. The site principal investigator [INVESTIGATOR_900594] l are responsible 
for knowing and adhering to their IRB requirements.  
DMID #[ADDRESS_1263046] 2019  
 
  
 
DMID/NIAID/NIH           [ADDRESS_1263047] submitted for them to the National 
Library of Medicine’s PubMed Central (http://www.ncbi.nlm.nih.gov/pmc/) an e lectronic 
version of their final, peer -reviewed manuscripts upon acceptance for publication, to be made 
publicly available no later than [ADDRESS_1263048] be accessible to the public on PubMed Central no later than 12 
months after publication.  
Refer to:  
NIH Public Access Policy, http://publicaccess.nih.gov/  
NIH OER Grants and Funding, http://grants.nih.gov/grants/oer.htm  
As of January 2018, all cli nical trials supported by [CONTACT_12242].gov, no later than [ADDRESS_1263049] applied for certification of delayed posting.  
As part of the result posting a copy of this protocol (and its amendments) and a copy of the  
Statistical Analysis Plan will be posted on ClincialTrials.gov.  
For this trial the responsible party is DMID which will register the trial and post results.   
The responsible party does not plan to request certification of delayed posting.  
Refer to:  
Publi c Law 110 -85, Section 801, Clinical Trial Databases  
42CFR11  
NIH NOT -OD-16-149 
DMID #[ADDRESS_1263050] 2019  
 
  
 
DMID/NIAID/NIH           97 
CONFIDENTIAL  
 Results of any exploratory immunogenicity analysis will not be published prior to publication of 
the primary immunogenicity results for this trial.  
*Journal Citation: De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. 
Clinical trial registration: a statement from the International Committee of Medical Journal 
Editors. N Engl J Med. 2004; 351:1250 -1. 
DMID #[ADDRESS_1263051] 2019  
 
  
 
DMID/NIAID/NIH           98 
CONFIDENTIAL  
 17 LITERATURE REFERENCES  
1. Hooper JW, Moon JE,  Paolino KM, et al. A Phase 1 clinical trial of Hantaan virus and 
Puumala virus M -segment DNA vaccines for haemorrhagic fever with renal syndrome delivered 
by [CONTACT_719487]. Clinical microbiology and infection : the official publication of 
the European Society of Clinical Microbiology and Infectious Diseases 2014;[ADDRESS_1263052] 5:110 -7. 
2. Jiang H, Zheng X, Wang L, Du H, Wang P, Bai X. Hantavirus infection: a global 
zoonotic challenge. Virologica Sinica 2017;32:32 -43. 
3. Simpson SQ, Spi[INVESTIGATOR_2988] L, Patel S, Faruqi I. Hantavirus pulmonary syndrome. Infectious 
disease clinics of North America 2010;24:159 -73. 
4. Boudreau EF, Josleyn M, Ullman D, et al. A Phase 1 clinical trial of Hantaan virus and 
Puumala virus M -segment DNA vaccines for hemorrhagic fev er with renal syndrome. Vaccine 
2012;30:1951 -8. 
5. Zhang YZ, Zou Y, Fu ZF, Plyusnin A. Hantavirus infections in humans and animals, 
China. Emerging infectious diseases 2010;16:1195 -203. 
6. Limongi JE, Oliveira RC, Guterres A, et al. Hantavirus pulmonary sy ndrome and rodent 
reservoirs in the savanna -like biome of Brazil's southeastern region. Epi[INVESTIGATOR_900595] 
2016;144:1107 -16. 
7. Martinez -Valdebenito C, Calvo M, Vial C, et al. Person -to-person household and 
nosocomial transmission of andes hantavir us, Southern Chile, 2011. Emerging infectious 
diseases 2014;20:1629 -36. 
8. Padula PJ, Colavecchia SB, Martinez VP, et al. Genetic diversity, distribution, and 
serological features of hantavirus infection in five countries in South America. Journal of clini cal 
microbiology 2000;38:3029 -35. 
9. Wells RM, Sosa Estani S, Yadon ZE, et al. An unusual hantavirus outbreak in southern 
Argentina: person -to-person transmission? Hantavirus Pulmonary Syndrome Study Group for 
Patagonia. Emerging infectious diseases 1997;3 :171-4. 
10. Nunez JJ, Fritz CL, Knust B, et al. Hantavirus infections among overnight visitors to 
Yosemite National Park, [LOCATION_004], [LOCATION_003], 2012. Emerg Infect Dis 2014;20:386 -93. 
11. Figueiredo LT, Souza WM, Ferres M, Enria DA. Hantaviruses and cardiopulmon ary 
syndrome in South America. Virus research 2014;187:43 -54. 
12. Auwaerter PG, Oldach D, Mundy LM, et al. Hantavirus serologies in patients 
hospi[INVESTIGATOR_496389] -acquired pneumonia. The Journal of infectious diseases 
1996;173:237 -9. 
13. Diglisic G, Rossi CA, Doti A, Walshe DK. Seroprevalence study of Hantavirus infection 
in the community based population. Maryland medical journal (Baltimore, Md : 1985) 
1999;48:[ADDRESS_1263053] hantavirus pulmonary 
syndrome (HPS) and hemorrhagic fever with renal syndrome (HFRS). Vaccine 2013;31:4314 -
21. 
DMID #[ADDRESS_1263054] 2019  
 
  
 
DMID/NIAID/NIH           99 
CONFIDENTIAL  
 15. Hannaman D, Dupuy LC, Ellefsen B, Schmaljohn CS. A Phase 1 clinical trial  of a DNA 
vaccine for Venezuelan equine encephalitis delivered by [CONTACT_900643]. Vaccine 2016;34:[ADDRESS_1263055] seoul virus infection. 
Virology 1999;255:269 -78. 
17. Kwilas S, Kishimori JM, Josleyn M, et al. A hantavirus pulmonary syndrome (HPS) 
DNA vaccine delivered using a spring -powered jet injector elicits a potent neutralizing antibody 
response in rabbits and nonhuman primates. Current gene therapy 2014;14:200 -10. 
18. Haese N, Brocato RL, Henderson T, et al. Antiviral Biologic Produced in DNA 
Vaccine/Goose Platform Protects Hamsters Against Hantavirus Pulmonary Syndrome When 
Adm inistered Post -exposure. PLoS neglected tropi[INVESTIGATOR_73065] 2015;9:e0003803.  
19. Hooper JW, Brocato RL, Kwilas SA, et al. DNA vaccine -derived human IgG produced in 
transchromosomal bovines protect in lethal models of hantavirus pulmonary syndrome. Science 
translational medicine 2014;6:264ra162.  
20. Li L, Petrovsky N. Molecular mechanisms for enhanced DNA vaccine immunogenicity. 
Expert review of vaccines 2016;15:313 -29. 
21. Sallberg M, Frelin L, Ahlen G, Sallberg -Chen M. Electroporation for therapeutic DNA 
vaccination in patients. Medical microbiology and immunology 2015;204:131 -5. 
22. Beckett CG, Tjaden J, Burgess T, et al. Evaluation of a prototype dengue -1 DNA vaccine 
in a Phase 1 clinical trial. Vaccine 2011;29:[ADDRESS_1263056] influenza by 
[CONTACT_900644] a viral protein. Science ([LOCATION_001], NY) 1993;259:1745 -9. 
24. Faurez F, Dory D, Le Moigne V, Gravier R, Jestin A. Biosafety of DNA vaccines: New 
generation of DNA vectors and curre nt knowledge on the fate of plasmids after injection. 
Vaccine 2010;28:[ADDRESS_1263057] 
genomic DNA following intramuscular injection and electroporation. Gene therapy 2004;11:7 11-
21. 
 
 
DMID #[ADDRESS_1263058] 2019  
 
  
DMID/NIAID/NIH           100 
CONFIDENTIAL  18 SUPPLEMENTS /APPENDICES  
DMID #[ADDRESS_1263059] 2019  
 
  
 
DMID/NIAID/NIH           101 
CONFIDENTIAL  Appendix A: Schedule of Events  
All Treatment Arms  
Study  Visit (V)  00 01 02 03 04 05 06 07 08 09 10 11 12 13 U/S# ET# 
Study  Day from Vaccine 1  Day < -28 
Screen  Day 1  
Vaccine 1  Day 8  
+2 Day 29  
+2 Day 36  Day 57  Day 64   
Day 85   
Day 141  Day 169  Day 176  Day 197  Day 253  Day 
337 - - 
Weeks from Vaccine 1   0 1 4 5 8 9 12 20 24 25 28 36 48 - - 
Study Day from Vaccine 2     Day 1  
Vaccine 2  Day 8  
+2 Day 29  
+2 Day 36  Day 57  Day 113 Day 141  Day 148  Day 169  Day 225  Day 
309 - - 
Study Day from Vaccine 3       Day 1  
Vaccine 3  Day 8  
+2 Day 29  
+2 Day 85  
+/-5 Day 
113+5 Day 120  Day 141  Day 197  Day 
281 - - 
Study Day from Vaccine 4           Day 1  
Vaccine 4  Day 8  
+2 Day 29  
+2 Day 85  
+/-5 Day 
169 
+/-7 - - 
Visit Type  Screen  Clinic  Clinic  Clinic  Clinic  Clinic  Clinic  Clinic  Clinic  Clinic  Clinic  Clinic  Clinic  Clinic  Clinic  Clinic  
Obtain Informed Consent∞ X                
Collect Demographic Information  X                
Height & Weight  X                
Physical Examination - Full X                
Urine Dipstick, Opi[INVESTIGATOR_319620]  X                
Screening Labs~  20= & 2                
Enrollment/Randomization   X               
Review Eligibility Criteria  X X†¬1  X†¬  X†¬    X†¬       
Medical History@ X X†¬1 X X X X X X X X X X X X X X 
Concomitant Medications 4 X√ X†¬ X X X X X X X X X X   X X 
Vital Signs (oral temp, pulse, BP)% X X†$  X†  X†    X†     X X 
Physical Examination – Targeted0  X X X X X X X X X X X X X X X 
Pregnancy Test ^ X X†  X†  X†    X†       
Clinical Safety Evaluations *  6.5 6.5  6.5  6.5   6.5 6.5    6.5 6.5 
                 
                 
                 
DMID #[ADDRESS_1263060] 2019  
 
  
 
DMID/NIAID/NIH           102 
CONFIDENTIAL  Study  Visit (V)  00 01 02 03 04 05 06 07 08 09 10 11 12 13 U/S# ET# 
Study  Day from Vaccine 1  Day < -28 
Screen  Day 1  
Vaccine 1  Day 8  
+2 Day 29  
+2 Day 36  Day 57  Day 64   
Day 85   
Day 141  Day 169  Day 176  Day 197  Day 253  Day 
337 - - 
Weeks from Vaccine 1   0 1 4 5 8 9 12 20 24 25 28 36 48 - - 
Study Day from Vaccine 2     Day 1  
Vaccine 2  Day 8  
+2 Day 29  
+2 Day 36  Day 57  Day 113  Day 141  Day 148  Day 169  Day 225  Day 
309 - - 
Study Day from Vaccine 3       Day 1  
Vaccine 3  Day 8  
+2 Day 29  
+2 Day 85  
+/-5 Day 
113+5 Day 120  Day 141  Day 197  Day 
281 - - 
Study Day from Vaccine 4           Day 1  
Vaccine 4  Day 8  
+2 Day 29  
+2 Day 85  
+/-5 Day 
169 
+/-7 - - 
Visit Type  Screen  Clinic  Clinic  Clinic  Clinic  Clinic  Clinic  Clinic  Clinic  Clinic  Clinic  Clinic  Clinic  Clinic  Clinic  Clinic  
PBMCs (ICS, LPA)   [ADDRESS_1263061] vax>  X  X  X    X       
Distribute Memory Aid/Materials   X  X  X    X       
Review Memory Aid/Site assessment    X  X  X    X    X X 
Assessment of Adverse Events   X X X X X X X X X X X   X X 
Assessment of SAEs   X X X X X X X X X X X X X X X 
∞  Prior to study procedures.  
†  Prior to study vaccination.  
¬  Review/confirm information or activity in subjects previously consented and screened. 
1  Review results of clinical screening laboratory evaluations.  
@  Complete medical history will be obtained by [CONTACT_319697] [ADDRESS_1263062] study vaccination.  
%  Subjects must not eat or drink anything hot or cold, or smoke within 10 minutes prior to taking oral temperature.  
$  Vital signs assessed on Day [ADDRESS_1263063] study vaccination will be considere d as baseline.  
√  All current medications and medications taken within [ADDRESS_1263064] vaccination  are collected 
in Advantage eClinicalSM. 
> Observation period will begin after the study vaccination has been given.   
^  Serum pregnancy test w ill be performed on all females of childbearing potential at screening . A urine pregnancy test will be performed  within [ADDRESS_1263065] be 
negative and known prior to each study vaccination.  
DMID #[ADDRESS_1263066] 2019  
 
  
 
DMID/NIAID/NIH           103 
CONFIDENTIAL  ~  Screening laboratories include: WBC, Hgb, platelet  count , ANC, sodium, potassium, Creatinine (Blood Urea Nitrogen [BUN] will be obtained only if creatinine is above the normal range), HgbA1C, 
total bilirubin, Alanine aminotransferase (ALT), hepatitis B surface antigen, hepatitis C antibody, HIV types 1 and 2  
=  All clinical screening laboratory evaluations are to be performed at sc reening and the values are to be reviewed prior to the first study vaccination on Day 1; no additional blood draws for this a re 
required on Day 1.   
&  Retesting of values that lead to exclusion is allowed once using an unscheduled visit during the screeni ng period, provided there is an alternative explanation for the out of range value.  
2  If the initial laboratory screening occurred more than 28 days before baseline (Day 1) but the subject was unable to be vacci nated within the 28 -day window (e.g., due to meeting Exclusion Criteria or 
for other reasons), the subject must have laboratories repeated.  
* Safety laboratories include: WBC, Hgb, platelet  count , ANC, sodium, potassium, Creatinine, total bilirubin, Alanine aminotransferase (ALT).  
#  Refer to protocol for specific procedures and time points for ET or U/S visit.  
3  The 2mg dosage cohort will receive 1mg/0.5ml  administered  into the left and right deltoid  muscles , one after another  or simultaneously . The 4mg  dosage  cohort will receive 2mg/0.5ml  administered  into the left and right deltoid  
muscles , one after another  or simultaneously .   
()  A targeted physical examination may be performed, if indicated based on review of medical history and any updates obtained by  [CONTACT_202415].  
4 Including solicitation for receipt of any non -study vaccines  
  
DMID #[ADDRESS_1263067] 2019  
 
  
 
DMID/NIAID/NIH           104 
CONFIDENTIAL  Appendix B: Acceptable Ranges of Screening Laboratory Measurements  
Lab Test Name  [CONTACT_900645], male  13.30 - 17.70  13.30  17.70  g/dL  
Hemoglobin, female  11.70 - 15.70  11.70  15.70  g/dL  
HgbA1C  na na <6.3  % 
White blood cell count (WBC) (18 to <21 years)^  4.5 – 13.0 3.6  13.0 K/mc L 
White blood cell count(WBC) (≥21 years)^  4.5 – 11.0 3.6 11.0 K/mc L 
Absolute Neutrophil count*  1.80 – 7.70 1.80 7.70 K/mcL  
Platelet count  135 - 466 135 466 K/mc L 
Sodium  136.0 – 145.0  136.0  145.0  mmol/L 
Potassium  3.5 – 5.1 3.5 5.1 mmol/L 
Blood urea nitrogen (BUN)† 9.0 – 23.00 <9.0 23.00 mg/dL  
Serum creatinine† ^, male  0.60 – 1.10 <0.60 1.3 mg/dL  
Serum creatinine† ^, female  0.50 – 0.80 <0.50 1.2 mg/dL  
Total bilirubin  0.10 – 1.2  0.10 1.2 mg/dL  
Alanine transferase† (ALT)  na na ≤49 unit/L 
Hepatitis B surface antigen  Negative  Negative  Negative   n/a 
Hepatitis C antibodies  Negative  Negative  Negative   n/a 
HIV -  1/2 Ab  Negative  Negative  Negative   n/a 
Serum hCG (females only)  Negative  Negative  Negative  n/a 
*  ANC for subjects that are of African American and Middle Eastern descent may have values as low as 0.8 K/mcL . 
Subjects of this descent must have an ANC ≥ 0.8 K/mcL  to be eligible to participate in the study if all other study 
criteria are met.   
†  Values of serum creatinine  and blood urea nitrogen (BUN) below the lower limit of normal (LLN) are a cceptable 
for study enrollment . 